General Medicine: organic click to four weeks on tirzepatide
End-to-end journey for a new patient who finds General Medicine through an organic Google result, starts tirzepatide, and reaches the week-4 dose decision. The journey is mapped at the level needed to build a technology plan and an operating plan.
Terms: GM is General Medicine; PC is the state professional corporation that furnishes care; PA is prior authorization; RTPB is real-time benefit check; NCPDP is the pharmacy provider identifier; PBM is pharmacy benefit manager; HIE is health information exchange; SKU is a sellable catalog item.
Evidence and gap legend. Observed means a specific source artifact or public response was inspected; it does not mean the full patient workflow was executed. Published means a company or vendor representation, not a measured SLA. Inferred means a plausible connection between observations. Proposed means a recommended future contract or control. Recovery gap means implementation was not available in the inspected material. Mapping gap means this document omits a required step. "No field in the inspected interface" does not mean "no capability anywhere at GM." No authenticated GLP-1 encounter, prescription, claim, checkout, fulfillment, or check-in was exercised.
Evidence tags: A:A1 means step A1 in evidence-A.md; that row carries the exact code path, URL, or dataset key. [INFERENCE] marks reasoning not directly observed.
0. Summary
General Medicine sells a visit, not a drug. A patient who clicks the organic GLP-1 evaluation result lands on a page that advertises a $25 estimated copay or a $100 cash video visit, creates a phone-only account with SMS OTP, autofills identity through Verified or falls back to manual entry, optionally checks insurance, answers a server-driven screening questionnaire, and books a video visit whose availability promise is today. The clinician writes a prescription, and that prescription becomes a separate pharmacy order the patient must route and pay for. The medication price is not part of the visit purchase: LillyDirect and Amazon quote $299 for the 2.5 mg KwikPen, retail quotes $496.12 to $508.09, and the public catalog does not quote this patient's insured drug cost. Four weeks of 2.5 mg are followed by a clinician review, a new prescription for 5 mg, a new order, and a new payment. The inspected client surfaces cover clinical workflow well. No pharmacy fulfillment event contract, dose-administration event, or dedicated prior-authorization case contract was recovered in those surfaces; production capability and staff workflows outside them are not established. The money is visit fees plus a $15 lab clinical fee; the drug price is a manufacturer pass-through with no observed General Medicine margin.
Key numbers
| Measure | Value | Basis |
|---|---|---|
| Time to first dose, cash retail pickup | 1 to 2 days, illustrative | [D:D17] [INFERENCE]: same-day video promise plus retail fill; no measured click-to-fill data |
| Time to first dose, cash LillyDirect or Amazon | No measured click-to-first-dose bound | LillyDirect publishes 3 to 5 business days after eRx receipt for verification and patient contact, then 1 to 4 days to process and ship after purchase. Transit, patient response, PA, stock and upstream care add time. Amazon timing is unverified. [PUBLIC https://www.lilly.com/lillydirect/faq] |
| Time to first dose, insured retail with PA | 5 to 13+ days | [LIVE GLP-1 guide, 2026-10-19]: PA takes several business days; [INFERENCE] on the rest |
| Initial visit plus first 28-day supply, cash KwikPen | $399.00 | $100 visit + $299 2.5 mg KwikPen. [LIVE /api/external/sku_options/300543] [LIVE /api/external/medication_option_skus/710641/cash_price] |
| Initial visit, first supply and Quest panel | $485.58 | Above plus $86.58 panel. [LIVE /api/external/lab_skus/503263] |
| Through purchase of the second fill | $984.58 | Above plus $100 week-4 visit and $399 5 mg KwikPen. Two 28-day drug purchases, not one month of medicine |
| Same two-fill scenario without panel | $898.00 | [E:E4.5] illustrative total |
| Same two-fill scenario with chat visits | $844.58 | $30 + $30 visits, same drug and lab prices. [LIVE /api/external/sku_options/300543] [LIVE /api/external/sku_options/300550] [LIVE /api/external/lab_skus/503263] |
| Insured path, estimated non-drug subtotal | $40.00 to $65.00 plus both fills and lab liability | $40 = initial $25 video copay + $15 lab review with no paid week-4 visit; $65 adds an estimated $25 follow-up. Both exclude drug and lab liability. [LIVE /api/external/sku_options/300543] [CODE components/Labs/AboutLabPricing.tsx:42-45] |
| First-fill drug spread | $299.00 to $1,100.16 | KwikPen 2.5 mg versus the default auto-injector, including the CVS upper bound. [LIVE /api/external/medication_option_skus/710641/cash_price] [LIVE /api/external/medication_option_skus/710642/cash_price] [A:A5.3] |
| Retail KwikPen range | $496.12 to $508.09 | Walgreens, Walmart, H-E-B versus CVS. [A:A5.3] |
| Exchange entries on the cash path | 32 entries including alternative pharmacy and lab channels; 72 in the register | A mandatory-party count for one journey is not established. [A:H1-H23] [B:H1-H22] [C:H1-H15] [D:H1-H18] [E:H1-H18] [F:H1-H25]; register §4 |
| Human touchpoints | 3 clinical roles, 1 dispensing pharmacist, 0 to 2 support | Mapping estimate, not observed volume. Initial prescriber [D:D5], lab reviewer [C:C21], week-4 prescriber [E:E7], pharmacist [D:D16] |
| Visit prices | $100 cash video, $25 estimated insured video, $30 cash chat | [LIVE /api/external/sku_options/300543, 2026-10-19] |
| Lab panel 503263 | $86.58 Quest, $109.67 Labcorp, $102.20 BioReference | [LIVE /api/external/lab_skus/503263, 2026-10-19]; includes the $15.00 clinical fee |
| Cancellation fee | $25.00 client fallback, video visits only, Medicaid exempt | [CODE utils/cancellationFeeUtils.ts:6-26]; the policy does not publish the amount |
| Refund request window | Visit fee 5 to 10 business days after eligible cancellation; lab refund request within 6 months if the sample is not collected, no deduction | [LIVE /cancellation-policy] [LIVE /refund-policy-labs] |
Top 10 risks and gaps, ranked
- The default Zepbound SKU costs 3.6 times the advertised price. The Lilly page says "from $299" and links to family SKU
201448, whose default child is710642at $1,074.09. The $299 price belongs to KwikPen SKU710641.[A:A5.1][LIVE /api/external/medication_option_skus/710642/cash_price = 107409] - No pharmacy fulfillment event contract was recovered. The inspected client surfaces expose a state string plus cancel and switch flags; acknowledgment, rejection, dispense, shipment and possession are not represented. Production may handle these outside the inspected surfaces.
[E:E1.3][CODE lib/store/api/pharmacyOrderApi.ts:15-24] - No dedicated prior-authorization case contract was recovered. RTPB returns a PA signal, but submission channel, evidence requests, approval scope, appeal and claim re-adjudication are not represented; who files and where is unverified.
[D:D5.2][LIVE /assignment-of-benefits] - The privacy review is incomplete. Recovered configuration shows no consent management platform, 100% session replay with
defaultPrivacyLevel: allow, and email plus phone in Segment events. Specific GLP-1 questionnaire capture, effective masking, retention, and destination access were not verified. Metabase's login shell is public; the reviewed response requires sign-in, and unauthenticated data access was not established.[A:A3.4][F:F4.1] - Billing helper literals differ from the reconstructed specification. The client checks
gm_cardandpharmacy_delegated; the reverse-engineered OpenAPI enum iscash,insurance,pharmacy_delegation. This is a source/specification inconsistency, not a demonstrated server defect; the authoritativeBillingTypeis unverified.[D:D5.4] - SEO sends crawlers to the wrong URLs. Sitemaps contain 3,184
/s/URLs; the brand medication pages among them arenoindex, nofollowand canonicalize to/dp/, while the indexable/dp/pages appear in no sitemap and have no internal links.[A:A2.1] - The week-4 refill window can create a gap after dose 4. One KwikPen supplies four weekly doses, used by T+21; the next dose is due T+28. GM's check-in trigger is unverified. Starting check-in and refill or PA work at T+28 can miss T+28 by 4 to 14 days. The proposed control is to start check-in and refill work at T+14 to T+18 and backward-plan from T+28. A T+21 eRx alone does not guarantee a T+28 dose for mail order, because 3 to 5 business-day verification plus processing and shipment can reach T+32.
[PUBLIC Zepbound PI §2.1][PUBLIC https://www.lilly.com/lillydirect/faq][E:E5][INFERENCE: proposed control] - The state-to-entity and licensure mapping is unverified. Legal documents name PCs in AZ, CA, KS, ID and NJ; NPPES records show different addresses and jurisdictions; a second consented network coexists. Address differences alone do not establish a licensure or CPOM defect.
[D:D0.3][F:F7] - Manufacturer savings and coordination of benefits are not represented. Eligibility, presentation, pharmacy, caps, renewal conditions, secondary claim and actual redeemed price are outside GM's public quote and were not exercised.
[D:D4.4][PUBLIC https://zepbound.lilly.com/savings] - Lab pricing is inconsistent across surfaces. Cards show the test price only; checkout adds $15.00; the client falls back to $30 when the field is missing;
platform_feeranges to $40 on panel 503263 and sits outside the total.[C:C4.3][F:F5.2]
1. Journey map
2. Timeline: click clock and treatment clock
Two clocks are required. E0 is the first organic click. T0 is the first actual administered dose, recorded as patient-reported or otherwise evidenced. T0 is never inferred from payment, eRx, dispense, delivery or possession. The first four injections are ordinarily T0, T+7, T+14 and T+21; the next scheduled weekly dose is T+28. Let Dstart be the elapsed days from E0 to T0. Dstart remains unknown until actual administration is reported; no bounded click-to-first-dose interval is established.
| Click clock | Tx clock | Event | Actor | Gate | Evidence |
|---|---|---|---|---|---|
| E0, 0 to 10 min | Pre-Tx | Organic result, landing page, CTA, signup redirect | Patient, Google, Vercel or Netlify | Page returns 200; CTA routes to /screen then /get-started |
[A:A1] [A:A4] [A:A6] |
| E0, 2 to 10 min | Pre-Tx | Phone, SMS OTP, session | Patient, Twilio, Cognito | US or territory NANP number; SMS deliverable | [B:B1-B2] |
| E0, 5 to 20 min | Pre-Tx | DOB, Verified autofill or manual entry; six consent booleans; HIE notice only on the manual about-you path | Patient, Verified, GM | 18+; US address in 50 states plus DC; email valid | [B:B3-B7] |
| E0, 10 to 30 min | Pre-Tx | Insurance discovery, optional; HIE chart review if records exist | Patient, eligibility service, Metriport or Particle | Payer found or self-pay chosen; consent; lookup hit | [B:B9-B10] |
| E0, 10 to 30 min | Pre-Tx | State confirmation, screening questionnaire, modality and slot | Patient | No red flag; video or chat available in state | [B:B11-B12] [C:C3-C5] |
| E0, 15 to 40 min | Pre-Tx | Visit fee paid or card saved; visit booked | Patient, Stripe | Slot available; card accepted | [C:C6-C7] |
| E0 to E+1 | Pre-Tx | Video visit about 20 minutes, or chat in the next window; clinical decision and eRx | Clinician, patient, Zoom or chat, DoseSpot, Athena | Clinician joins; identity and state confirmed; no absolute contraindication | [D:D3-D10] |
| E0 to E+3 | Pre-Tx | Baseline labs ordered, drawn, resulted; or external PDF uploaded | Clinician, Junction, Quest or Labcorp or BioReference | Requisition signed; sample collected; result reviewed if required before start | [C:C15-C22] |
| E0 to E+1 | Pre-Tx | Patient opens prescription, compares pharmacies, selects channel and billing type | Patient, GM, Arrive, pharmacy feeds | Valid NCPDP id; price available; required labs reviewed | [D:D11-D13] |
| Elapsed click-to-fulfillment time unknown; channel-specific planning estimates only | Pre-Tx | Pharmacy verification, checkout, claim or PA, shipment or pickup | Patient, pharmacy, PBM, PA team, carrier | Rx received; payment or claim; PA approved or cash chosen; stock available | [D:D14-D17] [PUBLIC https://www.lilly.com/lillydirect/faq] [INFERENCE: no measured bound] |
| E + Dstart | T0 | Dose 1, 2.5 mg, patient-reported. Possession, package condition, device and supplies confirmed first | Patient, pharmacist, care team | Drug in hand; presentation-specific instruction; T0 recorded or explicitly unknown | [E:E1.4-E2] [PUBLIC Zepbound PI §17] [INFERENCE: proposed T0 control] |
| E + Dstart + 7 | T+7 | Dose 2, 2.5 mg | Patient | Weekly schedule | [E:E4] |
| E + Dstart + 14 | T+14 | Dose 3, 2.5 mg; proposed check-in and refill work start | Patient, GM | One dose remains after this; start refill and PA work now | [E:E5] [INFERENCE: proposed control] |
| E + Dstart + 18 to 20 | T+18 to T+20 | Proposed check-in submission and clinician review; dose decision | Patient, clinician | Questionnaire, optional labs, interval history; reviewer available | [E:E6-E7] [INFERENCE: proposed control] |
| E + Dstart + 21 | T+21 | Dose 4, final 2.5 mg dose from the pen; refill work should already be underway | Patient, clinician, DoseSpot, pharmacy | Review complete; new strength prescribed; PA checked if insured. A T+21 eRx alone does not guarantee T+28 for mail order | [E:E8] [PUBLIC Zepbound PI §2.1] [PUBLIC https://www.lilly.com/lillydirect/faq] [INFERENCE: proposed control] |
| E + Dstart + 28 | T+28 | Dose 5, first 5 mg dose, if the second box is in hand; otherwise a gap | Patient | Box delivered or picked up by T+27 | [E:E8] [INFERENCE] |
| E + Dstart + 28 or later | T+28+ | Fallback review if the proposed T+14 to T+21 window was missed | Clinician, care team | Reconcile remaining pens, missed doses and restart plan | [E:E5-E7] [PUBLIC Zepbound PI §2.3] |
Timing note: only the video availability_promise: "today", the chat next-slot timestamp, LillyDirect's published minimum of 3 to 5 business days for verification plus 1 to 4 days to process and ship after checkout, the PA claim of "several business days", and the lab claim of 48-hour results are published. Lilly asks patients to allow a minimum of 3 to 5 business days for verification; most prescriptions are processed and shipped within 1 to 4 days of checkout. Transit and upstream delays are additional; these are not maximum delivery SLAs. Business days and calendar days are not interchangeable. No measured click-to-first-dose bound is established. The T+14 to T+18 refill start is a proposed operating control, not observed GM behavior, and a T+21 eRx is not sufficient to guarantee a T+28 mail-order dose.
3. Stage-by-stage walkthrough
A. Acquisition
Headline: one organic doorway works, and it sells a visit rather than a drug.
| # | Patient sees or does | GM system or route | Data | Outside party | Evidence |
|---|---|---|---|---|---|
| A1 | Clicks an organic result for a GLP-1 query | /s/glp-1-medication-evaluation/300543 on Vercel; article on Netlify |
Referrer, landing URL, IP, nile_ld_key UUID, isAuthenticated=false |
Google, Bing, DuckDuckGo, CloudFront, Vercel or Netlify | [A:A1] |
| A2 | Reads hero, price, FAQ, testimonials | SkuRefreshRenderer; category page components |
page_view_id, landing_page_loaded, dwell frames, LCP, cache hit |
Segment, Datadog, LaunchDarkly | [A:A2] |
| A3 | Nothing visible; attribution parameters are persisted when present | useAttributionTracking; POST /api/campaign-touches only when utm_source and an anonymous id exist |
UTMs, optional paid click IDs, _fbc, synthetic _fbp, in-app browser. An untagged organic landing creates no campaign touch |
Google, Microsoft, Meta, Kargo, OpenAI ads only when present; Segment | [A:A3] |
| A4 | Chooses Get started, Book a visit, a related service, or search | SkuDetailCta, CategoryHeader, ServiceItemCard, StoreSearchDrawer |
sf_clicked_sku, sku_page_cta_clicked, new_storefront_request_medication_clicked |
Segment, Datadog | [A:A4] [A:A11] |
| A5 | Is redirected to signup, or to login on /visit |
Edge middleware 307; sku_id and redirect_url cookies |
SKU id, absolute return URL, auth flag | None | [A:A6] |
| A6 | Enters phone, receives OTP | /get-started, /get-started/verify |
Phone, OTP funnel events | Twilio, AWS Cognito | [A:A7] [B:B1-B2] |
| A7 | Is returned to the booking screen, consumer not recovered so inferred | Cookie consumer not recovered | signup_complete, alias, identify, merge_identity, patientId |
Segment, Datadog | [A:A8] |
| A8 | On a medication page, switches dose form or strength | /dp/<slug>/<sibling_sku_id> via replaceState; price refetch |
New SKU id and price; no new pageview | None | [A:A10] |
| A9 | Searches "tirz", "zep", "glp" | /api/external/search/suggestions, /store/search |
Raw query and suggestion array sent to Segment | Segment | [A:A11] |
| A10 | Opens Browse pharmacies: API returns about 52 rows, UI caps display at 20 interleaved rows | pharmacy_comparisons API; Maps JS; UNIVERSAL_SEARCH_PHARMACIES_DISPLAY_LIMIT = 20 |
Coordinates, ZIP, NCPDP id, chain, distance, total_price_cents |
Google Maps, LillyDirect, NovoCare, Amazon, retail chains | [A:A12] [CODE components/Refresh/SearchResults/searchPharmaciesUtils.ts:12,154] |
| A11 | Lands on the Lilly co-branded page | /p/lilly/weight-loss |
landing_page_loaded with page_id=lilly_weight_loss; ad landing event |
Lilly, Segment | [A:A13] |
| A12 | Reads the GLP-1 guide and clicks Book visit | Astro article with absolute link | Outbound click; rel=noreferrer removes the referrer |
GA4, OneSignal, Sanity, Netlify | [A:A14] |
Decision points
- Visit or medication: the GLP-1 evaluation is
category: conditionand sells a visit. Medication SKUs sell a drug but cannot be bought before a visit. - Cash or insurance: the storefront has no global toggle. Condition and medication SKUs go straight to the booking screen; labs use an insurance drawer.
- Retail or direct: the compare drawer pins LillyDirect, NovoCare, and Amazon above retail. The price gap on the 2.5 mg pen is $299 versus $496.12 to $508.09.
- Which Zepbound form: the family page defaults to the auto-injector at $1,074.09. The KwikPen at $299 requires a dose-form switch or the LillyDirect pharmacy page.
B. Account and intake
Headline: phone-only signup, third-party identity autofill, six consent booleans plus an HIE notice, then a server-driven questionnaire.
| # | Patient sees or does | GM system or route | Data | Outside party | Evidence |
|---|---|---|---|---|---|
| B1 | Step 1 of 3, enters a US mobile number | /get-started, PhoneInput, AuthProvider.login |
POST /auth/initiate, phone in localStorage, otp_send_requested |
Twilio, Cognito | [B:B1] |
| B2 | Enters a 6-digit code | /get-started/verify |
OTP, Cognito session, HttpOnly cookie, isAuthenticated=true mirror |
Cognito, Twilio | [B:B2] |
| B3 | Step 3 of 4, enters date of birth | /get-started/date-of-birth |
{birth_date} only; no SSN field |
Verified | [B:B3] |
| B4 | Sees autofilled name, address, sex, email; no HIE notice observed on this path | /get-started/review-info |
Name, DOB, sex, email, up to 7 addresses | Verified | [B:B4-B5] |
| B5 | Manual about-you form with HIE notice and opt-out link | /get-started/about-you |
Legal name, address, email, sex at birth; HIE consent by continuing, PDF opt-out, no boolean field | Google Places, email validation vendor | [B:B6] |
| B6 | Accepts terms and continues | POST /api/external/patients |
Identity, six consent booleans hard-coded true, no HIE boolean, all UTMs and click IDs, signup_id, signup_sku_id, signup_channel |
Segment, Datadog | [B:B7] |
| B7 | Lands on /welcome or /ai/onboarding |
Auth-gated route; content not recovered | Conditional browser telemetry only: if SignupTracker mounts and its user, analytics and local-guard checks pass, it attempts signup_complete and identify, which carry email and phone; alias receives only the user ID. Sending on this path was not observed. Patient creation is the authoritative record |
Segment, Datadog | [B:B8] [CODE components/SignupTracker.tsx:16-98] |
| B8 | Insurance: picks a plan, enters member ID, or photographs the card | /insurance; eligibility enqueue or sync |
Payer, member ID, group, card images, copay, network status | Verified 1-Click Health (candidate), Waystar (inferred), payer, OCR vendor, S3 | [B:B9] |
| B9 | Reviews conditions, medications, allergies, procedures | /health-history/{step}/add |
FHIR records tagged metriport, particle, or customer |
Metriport, Particle | [B:B10] |
| B10 | Confirms physical state before screening | /location-confirmation |
appointment_location_state |
None | [C:C5] [D:D2] |
| B11 | Answers the GLP-1 screening questionnaire, one question per screen | /questionnaire/{id}/{n} |
Answers, progress, off_ramp_type in emergency, urgent, high_risk, requires_triage, unable_to_treat, different_sku; emergency branch |
None | [B:B11] [CODE lib/analytics/questionnaireInterstitialAnalytics.ts:3-9] |
| B12 | Picks video or chat and a time | /options, skuOptionsApi |
Modality, slot, price, insurance_status |
None at selection; Stripe at payment | [B:B12] |
| B13 | Completes history questionnaire or chart review before the visit | /questionnaire/{history_id}, /health-history |
Pre-visit requirements and responses | Metriport, Particle | [B:B13] |
Decision points
- Identity match or manual entry: a Verified miss produces no error message; the patient silently lands on the manual form.
- Insurance or self-pay: an eligibility failure offers "Try another insurance" or "Continue without insurance" at $100.
- Chat allowed or not: chat is omitted in AL, AR, DE, FL, KS, LA, MN, MS, NJ, NM, RI, and WV.
- Red flag or clear: the questionnaire can off-ramp to the care team, another SKU, or an unavailable screen.
C. Checkout and labs
Headline: three separate money events, and a lab fee that is real at $15 but fallback-priced at $30.
| # | Patient sees or does | GM system or route | Data | Outside party | Evidence |
|---|---|---|---|---|---|
| C1 | Sees Video $25 estimated or $100 cash; Chat $30 cash | /s/glp-1-medication-evaluation/300543 |
sku_id, price option |
None | [C:C1] |
| C2 | Taps Get started; screening flow opens | /s/{slug}/{id}/screen |
ref, practiceId, page view id |
None | [C:C2] |
| C3 | Answers screening questions | Questionnaire engine | screening_questionnaire_id=11340c6b..., answers |
None | [C:C3] |
| C4 | Chooses billing: insurance, cash, or MDSave where offered | /visit/{id}/options |
billing_type, price cents, insurance_status, slots |
MDSave on some in-person SKUs only | [C:C4] |
| C5 | Picks a slot; sees the 24-hour cancellation rule | /visit/{id}/schedule |
scheduled_time, clinician id, cancellation_fee_policy_applies |
None | [C:C5] |
| C6 | Sees Confirm and Book, due today, FSA/HSA label | /visit/{id}/payment |
payment_method_id, price_guaranteed, agreement flags |
Stripe | [C:C6] |
| C7 | Adds a card if none on file | SetupIntent then POST /visits/book |
client_secret, brand, last4, expiry |
Stripe | [C:C7] |
| C8 | Gets confirmation and a Zoom link | /visits/{id} |
visit_id, state, meeting_url |
Zoom, Twilio, email provider | [C:C8] |
| C9 | Cancels or reschedules | Visit state machine; Visitron fee waiver | cancellation_reason, cancellation_fee_amount_cents |
Stripe | [C:C9] |
| C10 | Later sees the prescription and pharmacy options | ensure_pharmacy_order; /orders/pharmacy/{id}/options |
pharmacy_order_id, medication_option_sku_id, NCPDP id, arrive_rtpbi_inquiry_id |
Arrive Health, DoseSpot | [C:C11-C12] |
| C11 | Chooses insurance copay, GM card at counter, or cash pre-pay | checkout, checkout_with_insurance, checkout_for_pharmacy_delegation |
billing_type, payment method, gm_card BIN/PCN/group/member |
Stripe, pharmacy | [C:C13-C14] |
| C12 | Orders a baseline lab panel or uploads recent labs | Lab SKU PDP; /account/medication-check-in/labs |
lab_sku_ids, lab_order_id, file ids |
Junction, Quest, Labcorp, BioReference, S3 | [C:C15-C22] |
| C13 | Sees test price plus "$15 clinical review added at checkout" | LabPanelPricing |
test_price, clinical_fee, clinical_fee_enabled |
None | [C:C18] |
| C14 | Books the draw; walks in or schedules | /s/{slug}/{id}/start; Junction appointment |
lab_order_id, accession, scheduled_at, lab_vendor_name |
Junction, lab | [C:C19-C20] |
| C15 | Gets results in dashboard, Updates, or PDF | /account/labs, Updates feed |
status, report_url, results_count, abnormal_results_count |
Lab, clinician | [C:C21] |
| C16 | Week 4: books follow-up or completes check-in | 300550; /prescriptions/{id}/check-in |
sku_id=300550, billing type, next fill |
Stripe, clinician | [C:C23-C24] |
Decision points
- Insurance in network: $25 estimate, preselected if cheaper.
- Out of network: book without insurance or switch to chat.
- Medicaid with no capacity: "Text us and we'll help you find a time."
- Lab self-bookable with insurance:
insurance_orderableis true for 503263; false for 500114, 500049, and 500001. - Lab conditions screen: continue without insurance, continue with insurance anyway, or book a video visit.
- Abnormal result: clinician outreach; a paid Lab Results Review visit exists at $100 or $25.
D. Clinical review and prescribing
Headline: a shift-based clinician writes the prescription in Visitron, and the pharmacy leg starts as a separate patient task.
| # | Patient sees or does | GM system or route | Data | Outside party | Evidence |
|---|---|---|---|---|---|
| D1 | Picks modality and slot; pays or saves a card, capture timing inferred | /options; visits/create, booking_selection, payment_method, book |
sku_id, modality, slot, price, state |
Stripe | [D:D1] |
| D2 | Confirms physical location | /location-confirmation |
State, practice_id, clinician pool |
None | [D:D2] |
| D3 | Waits for the visit link or chat window | Visitron appointment and chat queues | appointment_id, visit_type, meeting_url |
Zoom, Twilio | [D:D3] |
| D4 | Nothing; clinician opens the chart | applyAppointmentLatestPrewarm, getPatientChartContext, triggerMetriportSync, getQuestionnaireCodes |
HIE history, prior encounters, meds, allergies, answers | Metriport, Particle, Athena | [D:D4] |
| D5 | Talks or messages for 15 to 45 minutes | getDraftEncounter, updateDraftEncounter, getChatHistory, getNablaStatus |
Transcript, note draft, diagnoses, orders | Zoom, Zendesk, Nabla | [D:D5] |
| D6 | Describes weight history, comorbidities, prior GLP-1 use | Diagnosis and order search | BMI, comorbidities, contraindications, labs | None | [D:D6] |
| D7 | Later sees care-plan phases and check-ins | createCareJourney, changePathway, changePhase |
pathway_id, phase_id, modality, days supply |
None | [D:D7] |
| D8 | Nothing; later sees the prescription | createDraftPrescription, finalizeDraftPrescription; DoseSpot SSO |
Drug, strength, form, quantity, days supply, refills, SIG | DoseSpot | [D:D8] |
| D9 | Sees "available after visit" or a copay later | launchInsurancePrice, launch_benefit_inquiry; consumer poll |
Copay tier, deductible, formulary, PA flag, inquiry id | Arrive Health, DoseSpot, PBM | [D:D9] |
| D10 | Sees the signed care plan and next steps | confirmCarePlan, publishAppointmentDraftEncounter, syncEncounterToAthena |
Signed note, athena_id, next-step review |
Athenahealth | [D:D10] |
| D11 | Opens the prescription and taps order | ensure_pharmacy_order |
care_action_prescription_id, pharmacy_order_id, state |
None | [D:D11] |
| D12 | Compares pharmacies and selects one | pharmacy_comparisons, select_pharmacy |
NCPDP id, price, distance, fulfillment_owner |
LillyDirect, NovoCare, Amazon, retail | [D:D12] |
| D13 | Chooses cash, insurance, or pay at counter | PUT /api/external/pharmacy_orders/{id} with {billing_type} |
billing_type; payment method and price are separate fields |
Stripe, pharmacy | [D:D13] [CODE lib/store/api/pharmacyOrderApi.ts:34-42] |
| D14 | Pays or shows the GM card | checkout, checkout_with_insurance, checkout_for_pharmacy_delegation, gm_card |
payment_intent, gm_card fields |
Stripe, pharmacy | [D:D14] |
| D15 | Nothing; pharmacy receives the Rx | DoseSpot eRx to the selected NCPDP id | Rx payload, demographics, prepaid status | DoseSpot, pharmacy | [D:D15] |
| D16 | Gets a pharmacy text, checkout link, or pickup notice | Pharmacy system | Rx status, copay, PA status, savings, shipment | LillyDirect dispensing pharmacy, Amazon, retail | [D:D16] |
| D17 | Receives the package or picks up | No GM shipping object recovered | Pharmacy-side tracking is described; GM tracking visibility outside the inspected interfaces is unverified | Carrier, pharmacy | [D:D17] |
| D18 | At T+14 to T+28, sees check-in and next-step cards; GM trigger unverified | care_journey/next_steps, check-in |
Criteria id, responses, lab order, deadline | None | [D:D18] [INFERENCE: proposed window] |
| D19 | Week-4 visit or review; dose decision | getClinicianReviews, applyReview, changePhase, renewal |
New dose, new Rx, phase change, days supply | Clinician, Athena | [D:D19] |
| D20 | Chooses pharmacy and pays again for 5 mg | Same as D11 to D17 | New order, new SKU, new price, possibly new PA | All pharmacy parties | [D:D20] |
Decision points
- Zepbound or Mounjaro: separate indications. Zepbound weight management uses BMI 30 or 27 with a comorbidity; Mounjaro is type 2 diabetes and also has a cardiovascular-risk indication in specified adults with T2D. GM is adult-only and no pediatric redirect was observed; do not apply Zepbound BMI or cash rules to Mounjaro.
- Compounded tirzepatide: no SKU was observed in the inspected public catalog, search index or recovered source. Compounded products are outside this mapped branded path; availability elsewhere is not established.
- Form: KwikPen, auto-injector, or vial. The default PDP form is the auto-injector at $1,074.09; the vial has no cash price.
- Contraception: tirzepatide delays gastric emptying and can reduce oral contraceptive exposure, most after the first dose and each escalation. Counsel on a non-oral method or backup for 4 weeks after initiation and after each escalation; no structured field was observed and the counseling should repeat at week 4.
- Safety review: separate absolute label contraindications (MTC or MEN2 history, serious hypersensitivity) from warnings and precautions (gastroparesis, pancreatitis, gallbladder, kidney injury, hypoglycemia with insulin or secretagogues, retinopathy, pregnancy, anesthesia aspiration). Record the source version, finding, clinician decision and advice.
[PUBLIC Zepbound PI §§4-5, 7-8] - Cash or insurance: cash may use eligible retail pay-ahead, a pharmacy-counter cash or discount price, or an eligible manufacturer direct-pay program. Insurance needs a claim and may need a PA.
[D:D4.3][LIVE https://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup] - PA or no PA: RTPB returns a requirement; no dedicated PA case or submission contract was recovered.
[D:D5.2] - Week 4 for a new labeled Zepbound start: review at the end of four weeks of 2.5 mg and ordinarily proceed to 5 mg. Intolerance, interruption, extended initiation, switching or stopping require clinician-directed decisions; 2.5 mg is not a maintenance dose and no lower-than-2.5 mg starter dose is labeled.
[PUBLIC Zepbound PI §2.1]
Mounjaro adult T2D branch
- Indication: glycemic control in adults with type 2 diabetes, plus cardiovascular-risk reduction in specified adults with T2D; there is no BMI threshold for the T2D indication.
[PUBLIC Mounjaro PI §1] - Product route: separate NDC, presentation, quote, benefit or PA check, pharmacy and savings eligibility. Zepbound's $299/$399/$449 self-pay ladder does not apply.
[D:D4.2] - Observed GM route: retail only at $552.28 Walgreens and $565.63 CVS, a 2026-10-19 snapshot that must be re-quoted.
[LIVE /api/external/medication_option_skus/710655/cash_price] - Pediatric use: the Mounjaro label includes patients 10 years and older, but GM's observed service is 18+ with no pediatric redirect. Treat pediatric requests as out of scope for this path.
[PUBLIC Mounjaro PI §1][B:§5] - First-month dosing: start 2.5 mg once weekly. After at least 4 weeks, increase to 5 mg if additional glycemic control is needed; further 2.5 mg increments require at least 4 weeks on the current dose. Maximum 15 mg weekly in adults.
[PUBLIC Mounjaro PI §2.1] - Monitoring and handoff: record baseline glucose or A1c, diabetes medications, hypoglycemia risk, renal function and retinopathy history. Document any insulin or secretagogue dose reduction and the glucose-monitoring plan. At the first review, record glucose response, adverse effects, adherence and the clinician's continuation or escalation decision.
[PUBLIC Mounjaro PI §§5.3, 5.5, 5.7, 8] - Benefits: re-check the T2D indication, NDC, quantity, PA and savings eligibility separately from the Zepbound weight-management path.
[D:D4.2]
E. Pharmacy fulfillment and first dose
Headline: the prescription leaves GM and the patient becomes the integration.
| # | Patient sees or does | GM system or route | Data | Outside party | Evidence |
|---|---|---|---|---|---|
| E1 | Sees the care plan and prescription card | /account, /account/care-plans, /account/next-steps |
care_id, plan_id, plan state, remainingMessage |
None | [E:E1] |
| E2 | Chooses pharmacy and payment mode | ensure_pharmacy_order, pharmacy_comparisons, select_pharmacy |
NCPDP id, billing_type, prices, state |
Arrive, pharmacies | [E:E1.1] |
| E3 | Sees LillyDirect and Amazon at $299; retail at $496.12 to $508.09 | Compare drawer | Chain, distance, price, fulfillment_owner |
LillyDirect, Amazon, retail | [E:E1.2] |
| E4 | Pays in app, pays at counter, or presents the GM card | Stripe checkout; gm_card |
payment_method_id, BIN/PCN/group/member, submission state |
Stripe, pharmacy | [E:E1.3] |
| E5 | Gets a "prescription sent" notice; picks up or receives the box | No first-dose screen or event recovered | Prescription sent; no dose-taken timestamp recovered | Pharmacy, carrier | [E:E1.4] |
| E5.1 | Confirms possession, brand, strength, presentation, quantity, directions and package condition | Proposed possession reconciliation; no GM field observed | Presentation, quantity, condition, discrepancy | Dispensing pharmacy | [INFERENCE: proposed control] |
| E5.2 | Confirms needles, syringes and sharps plan; receives presentation-specific instruction and teach-back | Proposed; pharmacist and prescriber own counseling. AI is not a primary trainer | Presentation, supplies, ability, training version | Pharmacy, clinician | [PUBLIC Zepbound PI §17] [E:E2] [INFERENCE: proposed control] |
| E5.3 | Reports actual first dose as T0, or states that start is delayed or declined | Proposed T0 record; no administration endpoint observed | first_dose_administered_at, source, delay reason |
Patient, care team | [INFERENCE: proposed control] |
| E6 | Learns injection from the label, IFU, pharmacist or clinician; AI is a navigation aid, not a trainer | formatInstructions; patient_instructions; messaging |
SIG text, presentation, needle requirements | Pharmacy, Lilly | [E:E2] [PUBLIC Zepbound PI §17] |
| E7 | Messages the care team or General AI about side effects | Message Center if flag on; otherwise SMS; /ai |
Conversation, subject, response_expectation, AI messages |
Twilio, Zendesk, Braintrust | [E:E3] |
| E8 | Takes doses 2, 3, 4; no GM dose event recovered | None | No dose event observed in inspected client; production may differ | None | [E:E4] |
| E9 | Gets a refill reminder or check-in card | earliest_fill_date, criteria_deadline, NextStepCard |
Dates, pending criteria, deadline | None | [E:E5] |
| E10 | Completes check-in questionnaire and optional labs | /account/medication-check-in; care_journey/* |
Actionable count, estimated minutes, item type, status | Junction, lab, S3 | [E:E6] |
| E11 | Waits for clinician review | Visitron generateNextStepReview, applyReview, confirmNoChange |
Review fields proposed_json, final_json, rationale and phase are dossier-attributed, not first-party contracts |
Clinician | [E:E7] [F:F3.3] |
| E12 | Gets a new 5 mg prescription and pays $399 | New PharmacyOrder for new SKU |
New order id, SKU, price, PA requirement | Pharmacies, payer | [E:E8] |
| E13 | For the 7.5 to 15 mg KwikPen offer, completes the next qualifying purchase within 45 days of delivery or receipt of the previous fill | Refill or renewal next step | due_date, on_next_step, refills left, previous receipt date |
LillyDirect | [E:E9] [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] |
| E14 | Sees month-1 charges | /account/orders, pharmacy invoice |
Billing type, cash and insurance price, clinical fee, invoice | Stripe, pharmacy | [E:E10] |
| E15 | Cancels, switches pharmacy, declines renewal, or stops | pharmacy_orders/{id}/cancel, renewal decline |
Cancellation reason, cancel and switch flags | Support, pharmacy | [E:E11] |
| E16 | Does not log weight, doses, or vitals | No endpoint or device integration observed | Weight only if typed into a questionnaire | None | [E:E12] |
Decision points
- Mail order or retail: for the starter KwikPen snapshot, Austin retail quotes are $496.12 to $508.09 versus $299 direct, about 1.66 to 1.70 times. Different presentations and strengths need separate comparisons. Pickup may avoid transit, but stock and processing determine timing; no comparative delivery-performance distribution was measured.
- Pre-pay or pay at counter: pre-pay works at eligible retail only, not mail order.
- KwikPen or auto-injector: a $299 versus $1,074.09 decision that the storefront default gets wrong.
- Refill or renewal: same-strength refills depend on the prescription, pharmacy and payer rules; a new strength needs an appropriate new prescription.
[E:E9] - 45-day condition: for the 7.5, 10, 12.5 and 15 mg KwikPen purchase offer only, the next qualifying purchase must be completed within 45 days of delivery or receipt of the previous fill. The 2.5 mg and 5 mg starter prices are not conditioned on this window.
[PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions]
F. Weeks 1 to 4 and the week-4 step-up
Headline: the clinical loop is instrumented; the patient's month is not.
| # | Patient sees or does | GM system or route | Data | Outside party | Evidence |
|---|---|---|---|---|---|
| F1 | Home dashboard shows care plan and next steps | dashboard/show, next_steps/by_care, next_step_cards |
Plan state, next steps, deadlines | None | [E:E1] |
| F2 | Receives in-app, email, and SMS notices | Updates feed; email; Twilio | event_type, notifiable_type, unread, sla_promise |
Twilio, email vendor | [E:E14] |
| F3 | Asks General AI about missed doses or side effects | /ai, /ai/chat, /ai/health-records |
Consent, messages, feedback, Metriport prewarm | LLM provider, Metriport, Braintrust | [E:E13] |
| F4 | Reports severe symptoms or asks for a dose change | Message Center; 300348 side effect; 200010 adjustment |
Conversation, visit booking, clinical note | Twilio, Zendesk, clinician | [E:E16] |
| F5 | Completes the medication check-in; proposed unlock at T+14 to T+18, GM trigger unverified | /account/medication-check-in |
Answers, progress, estimated_minutes |
None | [E:E6] [INFERENCE: proposed control] |
| F6 | Completes or uploads labs if required | /labs, /labs/upload; care_journey/lab_bundle |
Lab order, file id, S3 state | Junction, lab, S3 | [E:E6] |
| F7 | Waits for a clinician decision | Visitron pending review | Review fields proposed_json, final_json, decision and rationale are dossier-attributed |
Clinician | [E:E7] [F:F3.3] |
| F8 | Gets 2.5 mg continued as a clinician deviation, or the standard 5 mg, or a stop | changePhase, changePathway, renewal ops |
New phase, strength, Rx, days supply | Athena, DoseSpot | [E:E7] [PUBLIC Zepbound PI §2.1] |
| F9 | Re-selects pharmacy and pays for the new strength | New order and checkout | New SKU id, NCPDP id, price, PA | Pharmacies, payer | [E:E8] |
| F10 | Refills or renews; may need a new PA | Refill order or NextStep::PrescriptionRenewal |
due_date, on_next_step, open_to_renew |
Pharmacy, PBM | [E:E9] |
| F11 | May stop without a formal workflow | Cancellation and renewal decline | Reason, flags, no subscription state | Support | [E:E11] |
| F12 | Remains outside any adherence measurement in the inspected client | No dose log, weight log or device sync observed | None | None | [E:E12] |
Decision points
- For a new labeled Zepbound start, ordinarily proceed from 2.5 mg to 5 mg after four weeks. Continuing 2.5 mg, extending initiation, lowering, switching or stopping are clinician-directed deviations; 2.5 mg is not a maintenance dose and no lower-than-2.5 mg starter dose is labeled.
[PUBLIC Zepbound PI §2.1] - Questionnaire only, labs, or a paid visit: the GLP-1 criteria set and blocking rule are server-side and unobserved.
- Refill timing: one KwikPen supplies four weekly doses; the fourth is used at T+21 and the next dose is due at T+28. Start check-in and refill or PA work at T+14 to T+18 and backward-plan from T+28. A T+21 eRx alone does not guarantee T+28 for mail order; GM's actual trigger is unverified.
[PUBLIC https://www.lilly.com/lillydirect/faq][INFERENCE: proposed control] - Adherence: no dose-administration event was recovered, so a stopped patient and a stable patient can look alike except through refill cadence or self-report.
[E:E4]
3.7 Product safety, dispensing and first-dose readiness
These are proposed controls. GM enforcement is not observed.
| Step | Patient sees or does | Responsible handoff | Proposed record or closure | What is known | Evidence |
|---|---|---|---|---|---|
| Safety review before prescribing | Discusses personal or family MTC or MEN2, serious hypersensitivity, pregnancy plans, GI history, diabetes drugs and other medications | Licensed prescriber reviews product-specific contraindications, warnings and interactions | Reviewed source and version, findings, decision, counseling, follow-up | PI content is established; exact GM questionnaire and rules are unrecovered. Do not relabel every warning as a contraindication | [PUBLIC Zepbound PI §§4-5, 7-8] [D:D6] |
| Contraception and planned procedures | Receives oral-contraceptive and procedure or anesthesia counseling when applicable | Prescriber to patient; pharmacist reinforces | Counseling documented, including non-oral method or barrier method for 4 weeks after initiation and each escalation | PI supports the counseling; structured GM enforcement unknown | [PUBLIC Zepbound PI §§7.2, 8.3, 17] |
| Pregnancy and interval review | Reports pregnancy, pregnancy plans or lactation at start and at follow-up | Prescriber; obstetric coordination when needed | Zepbound: discontinue when pregnancy is recognized. Mounjaro: product-specific diabetes and obstetric risk-benefit review. Interval pregnancy question at each escalation | PI supports product-specific actions; GM workflow unknown | [PUBLIC Zepbound PI §8.1] [PUBLIC Mounjaro PI §8.1] |
| Glycemic medication plan | Reports insulin, sulfonylurea or other glucose-lowering drugs | Prescriber and pharmacist | Baseline glucose or A1c, hypoglycemia risk, whether insulin or secretagogue dose reduction is indicated, monitoring plan | Labels require counseling and monitoring; no structured GM field observed | [PUBLIC Zepbound PI §§5.7, 7.1] [PUBLIC Mounjaro PI §§5.3, 5.7] |
| Narrow-therapeutic-index oral drugs | Reports warfarin, levothyroxine or other narrow-TI medicines | Prescriber and pharmacist | Delayed gastric emptying noted; monitoring or dose adjustment plan recorded | Label interaction section supports the risk; GM workflow unknown | [PUBLIC Zepbound PI §7.2] |
| Dispensing product reconciliation | Confirms brand, strength, presentation, quantity, directions and channel | Prescriber and eRx to dispensing pharmacist to patient | Accepted or corrected Rx and dispensed presentation; mismatch stays open | Gifthealth reports quantity, directions and formulation as rejection causes; GM route resolution unverified | [PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started] [D:D16] |
| Supplies and training | Confirms needles or syringes and sharps plan; receives device-specific instruction and ability assessment | Dispensing pharmacist and prescriber | Training version, received presentation, supplies, ability or assistance needed; retraining on presentation change | PI requires presentation-appropriate training. No completed GM training event observed. KwikPen needs a separate pen needle; no needle SKU was observed | [PUBLIC Zepbound PI §17] [E:E2] [E:§6 q14] |
| Shipment or pickup exception | Reports wrong item, delay, damage, suspected temperature problem or non-possession | Pharmacy handles product and dispensing decision; GM coordinates clinical consequences | Tracking if available, possession report, issue, pharmacy response, replacement or clinical plan | Use the received presentation's current label. Do not infer safety from a carrier scan. GM visibility unknown | [D:D5.3] [PUBLIC Zepbound PI §16.2] [INFERENCE: common practice] |
| Cold chain and in-use storage | Stores and uses the received presentation correctly | Pharmacist reinforces at dispensing; patient follows IFU | Refrigerate at 2 to 8 C, never freeze; room temperature means no more than 30 C. Total room-temperature exposure is cumulative. Never use a previously frozen product. Single-dose pen or vial: up to 21 total days at 30 C or below, then discard. Unopened multi-dose vial or KwikPen at room temperature: discard after 30 days. Opened multi-dose vial or KwikPen: discard after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first | Label supplies concrete limits; no GM temperature-tracking feed recovered, production visibility unknown | [PUBLIC Zepbound PI §16.2] |
| First-dose start | Reports actual start or explains delay or decline | Patient to care team | T0 with source, or explicit unknown or not started; next-dose plan | Proposed control; no administration endpoint observed | [INFERENCE: proposed control] |
| Safety event and product complaint | Receives urgency-appropriate clinical direction | Licensed clinician first; reporting owner separately reviews Lilly or FDA reporting | Clinical event and action, product and exposure details, report reference if submitted, follow-up | PI reporting routes observed; GM reporting practice unknown. Reporting is not a substitute for emergency care | [PUBLIC Zepbound PI §17] [E:E16] |
3.8 Prior authorization and claim closure
A benefit inquiry is not a PA submission, an approval is not a paid claim, and a paid claim is not dispense. This lifecycle is proposed and must be reconciled with existing DoseSpot, payer portal, Athena and staff processes before building a second queue.
| State or event | Owner and handoff | Minimum record | Exit or failure | Evidence |
|---|---|---|---|---|
| Benefit signal or claim rejection received | Pharmacy or benefit service to a verified PA intake owner | Patient, prescription, product and NDC, payer or PBM, rejection or PA signal, source time | Accepted case ownership, not just a patient notification | [D:D5.2] [D:D9] |
| Requirements and coverage checked | PA specialist plus prescriber | Plan criteria, evidence needed, authorization scope, urgency, submission channel | Missing-evidence task or ready-to-submit; channel currently unknown | [D:D5.2] [F:F6] |
| Submitted | Verified submitter to payer or PBM | Submission timestamp, external receipt or case number, document versions | Acknowledged submission, not inferred from a button click | [INFERENCE: proposed control] |
| Additional information requested | Payer to case owner to prescriber or patient | Request, deadline, owner, response receipt | Response accepted or deadline escalation | [INFERENCE: proposed control] |
| Decision | Payer to case owner to patient or pharmacy | Approval or denial reason, covered strength and form, quantity, effective and expiry dates, appeal rights | Approval is not yet a successful fill | [INFERENCE: proposed control] |
| Re-adjudicated | Pharmacy to PBM | Actual claim outcome, patient liability, savings result | Patient accepts payable amount or chooses another authorized path | [D:D5.3] |
| Savings and COB | Pharmacy benefit service | Program and offer version, product and presentation, approved-use eligibility, government-program exclusion, permitted pharmacy, quantity and days supply, primary claim outcome, secondary claim result, remaining cap, expiration, patient's accepted price | Missing eligibility or denied secondary claim explained before a replacement cash price | [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] |
| Denial, cash, appeal or switch | Prescriber, patient and PA owner | Clinical choice, explicit financial acceptance, appeal deadline, replacement prescription if needed | Do not silently convert to cash or presume reimbursement permitted | [D:D5.2] [E:E16] |
| Dispensed, reversed or abandoned | Pharmacy to care coordination, where supported | Dispense or reversal evidence, patient possession, closure reason | Case closure with evidence; abandoned is not successful care | [E:E1.3] |
| Next strength or renewal | Prescriber, PA owner and pharmacy | Remaining authorization and refills, next-dose date, product change, lead time | Resolve before a planned interruption; do not auto-escalate | [E:E8] [E:E9] |
3.9 Operational and legal handoffs
| Task | Accountable role, proposed | Required handoff or artifact | Current evidence limit | Evidence |
|---|---|---|---|---|
| Encounter location and clinical authority | Clinical operations or licensed clinical lead | Current physical state, callback, clinician eligibility, furnishing entity, collaboration requirements. If location changes, authority expires, or no eligible clinician exists, hold unsupported care and route to a licensed reviewer. Pharmacy refusal of an NP prescription escalates to the licensure manager | Public modality availability and location route observed; backend enforcement unverified | [B:B11] [C:C5] [F:F8] |
| Self-pay estimate | Billing and compliance owner for the furnishing provider | Request or scheduling trigger, uninsured or self-pay status, issuing entity, dated itemized estimate, delivery evidence, dispute intake. Scheduling 3 to 9 business days ahead: deliver within 1 business day. 10 or more business days ahead, or requested before scheduling: within 3 business days. Separately billed labs and pharmacies may issue separate estimates | Prices observed; a compliant good-faith estimate artifact was not recovered | [PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate] |
| Medical record access, transfer and retention | Record custodian or privacy officer for each relevant entity | Request verification, applicable deadline, export delivery, amendments, retention and legal hold, vendor copies, audio retention. HIPAA documentation must be retained at least 6 years. State medical-record retention varies by jurisdiction and entity; confirm it. Define S3 lifecycle for card images and lab PDFs and a post-sign-off audio policy | No complete retention or custody workflow recovered | [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.530] [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.524] [F:F8] |
| Clinical adverse event | Licensed clinical lead | Urgent triage, clinical documentation, care plan; separate reporting review | Generic messaging and label routes observed; completed workflow not observed | [PUBLIC Zepbound PI §17] [E:E16] |
| Dispensing and counseling | Dispensing pharmacy | Product acceptance, counseling, supplies, storage and replacement decision | External channel instructions observed; GM acknowledgment feed unknown | [PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started] [D:D16] |
| Refund | Billing or support owner | Request, policy eligibility, original transaction, amount, execution reference, notice | Visit and lab policies observed; execution system unverified | [LIVE /refund-policy-labs] [C:C4.4] |
| Account closure or treatment stop | Privacy, billing and clinical owners by distinct task | Stop or transfer plan, future-order disposition, financial obligations, retention explanation | Cancellation and decline actions do not establish all closures | [E:E11] [INFERENCE: common practice] |
4. Vendor and partner handoff register
The six evidence files contain 121 handoff rows. They collapse to 72 exchange entries below: one row per company or product per distinct data exchange and mechanism. A row marked * is on the cash path, including alternative pharmacy and lab channels. The register spans 32 cash-path entries, 72 total exchanges, and multiple products from single companies. A mandatory-party count for one journey is not established, and several rows are price feeds rather than prescription handoffs.
PHI column: Yes marks potentially identifiable health information, not an automatic BAA requirement. No means no patient identifier or clinical payload was observed. Unknown means the payload was not observable. Determine whether each recipient is a business associate, independent treating provider, payer or another legally permitted recipient. Privacy and legal own the disclosure basis and contract classification; BAA execution status remains unverified. [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.502] [F:F8]
| # | Stage | Counterparty (company / product) | Direction | Data exchanged | Mechanism | Trigger | Who pays / fee | PHI? | Confidence | Evidence |
|---|---|---|---|---|---|---|---|---|---|---|
| H01* | A | Google, Bing, DuckDuckGo organic search | Inbound | Query, referrer, landing URL, UA, IP | HTTP referral | Organic click | None to GM; SEO cost | No | Observed | [A:H1] |
| H02 | A | Google Ads | Inbound | gclid, gbraid, wbraid, landing URL |
URL query to 7-day cookie to CampaignTouch | Paid click | GM ad spend, unknown | No | Observed | [A:H2] |
| H03 | A | Microsoft Advertising | Inbound | msclkid |
URL query to cookie | Paid click | GM ad spend, unknown | No | Observed | [A:H3] |
| H04 | A | Meta Ads | Inbound | fbclid, _fbc, synthetic _fbp, in-app browser flag |
Cookie plus CampaignTouch, no pixel | Paid social click | GM ad spend, unknown | No | Observed | [A:H4] |
| H05 | A | Kargo | Inbound | kad_cid |
URL query to cookie | Mobile ad click | GM ad spend, unknown | No | Observed | [A:H5] |
| H06 | A | OpenAI ChatGPT Ads | Inbound | oppref |
URL query to cookie | ChatGPT ad click | GM ad spend, unknown | No | Observed | [A:H6] |
| H07* | A, B | Segment, Twilio | Outbound | Page views, events, email, phone, click IDs, search queries, SKU and price context, tenant slug | JS SDK to evs.segment.generalmedicine.co |
Every page and action | GM subscription; BAA unknown | Yes at signup | Observed | [A:H7] [B:H17] |
| H08* | A, B | Datadog RUM and Logs | Outbound | Session replay DOM and text, interactions, resources, errors, console logs, user id, flags, API latency | Browser SDK | Every page and action | GM SaaS; BAA unknown | Yes on clinical pages | Observed | [A:H8] [B:H18] |
| H09* | A, B | LaunchDarkly | Outbound | Context key, flag evaluations | React SDK with useReport |
Every render | GM SaaS | No | Observed | [A:H9] [B:H20] |
| H10 | A, B | Google Analytics 4 | Outbound | Page location, referrer, client id, engagement | gtag.js, G-9WGCRPWTXD |
Marketing page load | Free | No | Observed | [A:H10] [B:H19] |
| H11 | A | OneSignal | Outbound | Push player id, browser, site | Web SDK v16 | Marketing page load | GM SaaS | No | Observed | [A:H11] |
| H12 | A | Sanity | Inbound | Article and bio content, images | CDN plus build or SSR CMS | Page render | GM SaaS | No | Observed | [A:H12] |
| H13* | A, B | Google Maps Platform | Both | Address keystrokes, place ids, coordinates, ZIP, map viewport | Maps JS, Places, Geocoding | Address entry and compare drawer | GM API usage | Yes, address | Observed | [A:H13] [B:H6] |
| H14 | A | Vimeo | Outbound | Video requests, referrer, IP | Progressive player | Video play | GM plan | No | Observed | [A:H14] |
| H15* | A | Netlify, Vercel, CloudFront | Both | Request logs, IP, headers | Hosting and CDN | Every request | GM hosting | No | Observed | [A:H22] |
| H16 | A, F | Slack | Nile-Core to Slack | Session replay links and alerts | Backend job to Slack webhook, dossier-attributed | PDP, pharmacy or homepage view, deduped one per user per hour | GM Slack plan | Potential | Direction observed; job name and dedupe dossier-attributed | [A:H23] [F] |
| H17 | A | Trustpilot | Outbound link | None beyond the click | Link | User click | None | No | Observed | [A:H20] |
| H18 | A, F | LegitScript | Outbound link | None beyond the click, badge asset | Link and badge | User click | Certification fee, unknown | No | Observed | [A:H21] [F] |
| H19* | A, E | LillyDirect Pharmacy, price feed | Inbound to GM | Price, NCPDP 1574056, friendly id 88334 |
REST pharmacy_comparisons plus directory page |
Compare drawer or Lilly page | Margin unknown | No | GM response observed; upstream supplier contact unverified | [A:H15] |
| H20 | A | NovoCare, price feed | Inbound to GM | Price, NCPDP 5758074, friendly id 84293 |
REST | Compare drawer | Margin unknown | No | GM response observed; upstream supplier contact unverified | [A:H16] |
| H21* | A | Retail chain price feed, CVS, Walgreens, Walmart, H-E-B, Randalls, Sam's Club | Inbound to GM | Chain, NCPDP, address, distance, total_price_cents |
REST | Compare drawer | Margin unknown | No | GM response observed; upstream supplier contact unverified | [A:H17] |
| H22* | A, D | Amazon Pharmacy, price feed | Inbound to GM | Price, NCPDP 5919177 |
REST | Compare drawer | Margin unknown | No | GM response observed; upstream supplier contact unverified | [A:H17] [D:H11] |
| H23* | B, C, D, E | Stripe | Both | SetupIntent, payment method, brand, last4, charge, 3DS, refund | REST plus Stripe.js | Card add, visit booking, pharmacy cash checkout | Patient pays; GM processing fee | Yes, payment metadata | Observed | [B:H21] [C:H1] [D:H9] [E:H10] |
| H24 | B, C | Persona | Persona-related verification routes recovered; browser, vendor and backend transport unverified | Government ID, selfie, name, DOB, inquiry result | Routes and generic pre-visit requirement only; transport and GLP-1 activation unverified | In-person verification and generic pre-visit requirement; GLP-1 trigger unknown | GM per inquiry | Yes | Routes observed; transport and GLP-1 activation unverified | [B:H22] [C:H13] |
| H25* | B, C, E | Twilio Programmable SMS and Verify | Outbound | Phone, 6-digit code, delivery result | REST from a Cognito Lambda trigger | OTP | GM per message | Yes, phone | Observed | [B:H1] |
| H26* | B, C | AWS Cognito | Both | Phone, OTP challenge and session, tokens, isExistingUser |
CUSTOM_AUTH behind /auth/* |
Every login and signup | GM per MAU | Yes | Observed | [B:H2] |
| H27 | B | Google Identity and OAuth | Both | Email, profile, OAuth state, token | Redirect and REST | Google button where enabled; not rendered on DTC | Free | Yes | Observed | [B:H3] |
| H28* | B | Verified, 1-Click Signup | Both | Phone plus DOB in; name, DOB, sex, email, addresses out | REST via Nile-Core | After OTP on DOB submit | GM per lookup | Yes | Observed | [B:H4] |
| H29 | B | Verified, 1-Click Health | Both | Name plus DOB to member id, payer, eligibility | REST | DOB submit or insurance step | GM per lookup | Yes | Inferred | [B:H5] |
| H30 | B | Email validation vendor, unnamed | Both | Email to isValid |
REST | About-you submit when flag on | GM per validation | Yes | Observed | [B:H7] |
| H31 | B, C | Waystar | Both | X12 270 and 271: member, payer, service type to eligibility, copay, network, deductible | EDI via connector | Insurance onboarding | GM transaction fee | Yes | Inferred | [B:H8] |
| H32* | B, C, D, E | Payer and PBM eligibility | Both | Plan, network, copay, deductible, PA rules | EDI 271 via clearinghouse | Eligibility query | Payer adjudicates | Yes | Observed request, inferred payload | [B:H9] [C:H11] [D:H14] |
| H33 | B | Payer directory provider, unnamed | Inbound to GM | Payer list, payer ids | GET /insurances/directory_payers |
Insurance search | GM vendor fee, unknown | No | Observed | [B:H10] |
| H34 | B | Card OCR provider, unnamed | Both | Card image ids to payer, member id, group, plan, then eligibility | trigger_card_image_eligibility_check |
Patient photographs card | GM per call | Yes | Inferred | [B:H11] |
| H35 | B, C, E | AWS S3 | Both | Insurance card, external lab PDF, file ids, presigned URL | Presigned PUT then complete |
Upload | GM storage | Yes | Observed | [B:H12] [C:H8] [E:H14] |
| H36* | B, D, E | Metriport | Both | Identity and consent to FHIR conditions, medications, allergies, procedures | REST and FHIR | HIE lookup, chart prewarm, AI prewarm | GM per retrieval | Yes | Observed | [B:H13] [D:H8] [E:H6] |
| H37* | B, D, E | Particle Health | Both | Same clinical domains, availability check | REST | Where Metriport lacks records | GM per query | Yes | Observed | [B:H14] [D:H8] [E:H6] |
| H38* | B, C, D, E | Emerald Medical Practice, P.C. and P.A. | Both | Identity, consents, HIE authorization, insurance assignment, clinical record, claims | Click-through consent, assignment of benefits, claims | Signup and every billed encounter | Patient copay or cash; PC bills payer; GM MSO fee unknown | Yes | Observed | [B:H15] [C:H10] [D:H1] [E:H1] |
| H39 | D, E | Ruby Medical Practice, P.C. and Centennial Medical Practice, P.C. | Both | Same as H38 | Consent plus Visitron assignment | Patient in NJ or ID | Same as H38 | Yes | Observed | [D:H2] [E:H1] |
| H40 | B, D, E | OpenLoop Healthcare Partners, Reliant.MD, MECNB under the Vital consent | Both | Telehealth consultation, consent, state entity, clinician credentials | Network contract plus consent page | If the visit routes to that network | Network bills; GM coordinates | Yes | Inferred trigger | [B:H16] [D:H3] [E:H2] |
| H41 | C, F | Trust Commerce | Both | guarantor_id, billing_ids, single-use token bound to visit and patient |
Hosted page plus callback | Mercy tenant billing only | Mercy patient | Yes | Inferred | [C:H2] |
| H42* | C, D, E | Arrive Health | Both | Patient, drug, pharmacy to copay, deductible, formulary, PA signal, inquiry id | REST and OAuth launch | Pharmacy selection | GM per transaction | Yes | Observed | [C:H3] [D:H7] [E:H4] |
| H43* | C, E, F | Junction and Vital | Both | Patient, order, lab test ids, billing type, sample id, status, results, critical webhook, biomarker catalog | REST and webhooks | Lab order and result | Test price plus clinical fee; split unknown | Yes | Observed | [C:H5] [F] |
| H44* | C, E | Quest Diagnostics | Both | Requisition, accession and sample id, specimen, results, PDF | LIS via Junction | Draw | Cash patient pays GM; insurance lab bills insurer | Yes | Observed | [C:H6] [E:H13] |
| H45* | C, E | Labcorp | Both | Same as H44 | LIS via Junction | Draw | Same as H44 | Yes | Observed | [C:H6] |
| H46* | C, E | BioReference | Both | Same as H44 | LIS via Junction | Draw | Same as H44 | Yes | Observed | [C:H6] |
| H47* | C | Ordering physician, Junction-assigned or GM clinician | Both | Ordering provider name and NPI, critical-result call, interpretation and sign-off | Junction network or Visitron | Every lab order and every critical result | $15 clinical review; split unknown | Yes | Observed role, inferred mode | [C:H7] |
| H48 | C | MDSave | Both | mdsave price option, md_save agreement flag |
Offer in booking options | In-person or urgent care only, not 300543 | Patient pays voucher price | Yes | Observed absence on path | [C:H12] |
| H49* | D, E, F | Athenahealth | Both | Encounter note, diagnoses, orders, care plan, athena_id |
REST sync and resync | Clinician publishes or plan changes | GM license | Yes | Observed | [D:H4] [E:H5] [F] |
| H50* | D, E, F | DoseSpot | Both | Patient context, eligibility, formulary, draft and final Rx, EPCS identity, inbound refills | SSO, REST, NCPDP SCRIPT | Prescribe or renew | GM license | Yes | Observed | [D:H5] [E:H3] [F] |
| H51 | D, E, F | Nabla | GM and clinician to Nabla audio and context; Nabla to GM draft and status | Audio, transcript, note draft, status; transmitted content unverified | Embedded scribe | Clinician starts scribe | GM license | Yes | Status operation observed; audio payload unverified | [D:H6] [F] |
| H52* | D, E | LillyDirect Pharmacy, LLC, NCPDP 1574056, NPI 1912889320 |
GM to LillyDirect | Rx, name, DOB, contact, NCPDP id, payment or insurance context | eRx to NCPDP id, phone or fax fallback | Patient selects LillyDirect | Patient pays dispensing pharmacy; GM pay-ahead not available at mail order | Yes | Endpoint observed; downstream product route unverified | [D:H10] [E:H7] |
| H53* | D, E | LillyDirect dispensing pharmacies, Amazon, Fuze Health, Gifthealth, Prescryptive, Walmart | Pharmacy to patient | Verification, checkout link, price, delivery or pickup, tracking, savings applied | SMS, email, checkout | Rx received | Patient pays pharmacy | Yes | Destination set observed; product-level route unverified. Gifthealth publishes NCPDP 3692539 for its self-pay channel |
[D:H16] [PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started] |
| H54* | D, E | Amazon Pharmacy, NCPDP 5919177, NPI 1285084467 |
GM to Amazon | Rx, patient identifiers, payment context | eRx to NCPDP id | Patient selects Amazon | Patient pays Amazon | Yes | Observed | [D:H11] [E:H8] |
| H55 | D, E | NovoCare, NCPDP 5758074, NPI 1710671854 |
GM to NovoCare | Rx and patient identifiers, for Wegovy | eRx to NCPDP id | Patient selects NovoCare | Patient pays NovoCare | Yes | Observed | [D:H12] |
| H56 | D, E | Retail pharmacy, CVS, Walgreens, Walmart, Costco, Safeway, Kroger, Rite Aid, Alto | Both | Rx, NCPDP id, demographics, prepaid notice or GM card, claim | eRx plus NCPDP claim | Patient selects retail | Cash: patient pays GM or pharmacy; insured: PBM pays pharmacy and patient pays copay | Yes | Observed | [D:H13] [E:H9] |
| H57 | D, E | PBM and payer claim adjudication | Pharmacy to PBM | Claim, member id, NDC, days supply, copay, PA | NCPDP Telecommunication | Fill | PBM pays pharmacy | Yes | Inferred | [D:H14] |
| H58* | D, E, F | Lilly and Novo savings programs, EVERSANA PTR | Manufacturer to pharmacy and patient | Savings card BIN and PCN, eligibility, PTR claim; offer version, payer eligibility, caps and actual redemption unverified | Pharmacy claim plus manufacturer PTR at eversana-ptr.virtualrx.co |
Eligible fill | Manufacturer funds; patient pays reduced copay | Yes | Program terms published; GM eligibility and redemption unverified | [D:H15] [PUBLIC https://zepbound.lilly.com/savings] |
| H59 | D, E | Retail or LillyDirect pharmacy to GM | Inbound | Refill request, Rx status, rejection, PA request | eRx inbound, fax, phone, message subject pharmacy_order |
Refill or claim issue | No direct fee | Yes | Observed | [D:H17] |
| H60 | D, E | GM operations to payer, PA submission | Outbound | PA form, chart evidence, letter of medical necessity, appeal; lifecycle in §3.8 | Unknown: portal, fax, or phone; no ePA evidenced | PA required or denied | GM staff time | Yes | Inferred; channel unknown | [D:H18] |
| H61* | D, E, F | Zoom | Outbound | Unique meeting URL, meeting id, passcode | Link by SMS and email | Video visit booked | GM pays Zoom | Yes | Observed | [D] [E:H12] |
| H62 | E | Twilio Conversations and SMS short code 98528 | Both | Chat token, messages, attachments, SMS | JWT plus REST | Patient messages or receives reminder | GM per message | Yes | Observed | [E:H11] |
| H63* | E | Email provider, unidentified | Outbound | Visit link, lab notice, prescription notice, care plan | Email API or SMTP | Events | GM vendor | Yes | Observed channel, vendor unknown | [E:H15] |
| H64 | E | Braintrust | Outbound | AI span score, thumbs category and comment | /api/chat/feedback |
Patient rates an AI answer | GM | Potential | Observed | [E:H16] |
| H65 | E, F | Databricks and Metabase | Internal | Warehouse tables to dashboards | Metabase Databricks driver | Analyst query | Unknown | Potential | Observed | [E:H17] [F] |
| H66* | E | Eli Lilly, IFU and Medication Guide, MedWatch | Lilly to patient labeling; patient or clinician to Lilly or FDA safety report | Instructions for use, adverse-event and product-complaint report | Paper insert, LillyDirect, 1-800-LillyRx, FDA MedWatch | First fill, side effect or product complaint | Patient pays drug and needles | Yes for the report; No for the label | Observed routes; GM reporting practice unknown | [E:H18] [PUBLIC Zepbound PI §17] |
| H67 | E, F | Zendesk | Internal | Async chat and triage threads, clinician replies, attachments | Agent workspace | Chat visit or triage message | Subscription | Yes | Observed | [F] |
| H68 | F | Ashby | Both | 16 requisitions, applications | Hosted job board and API | Recruiting | Plan | No | Observed | [F] |
| H69 | D, F | CMS NPPES and NPI Registry | Outbound query | NPI, legal name, address, taxonomy | Public API | Entity verification | None | No | Observed | [D:source appendix] |
| H70 | F | CMS Medicare Part D and GLP-1 Bridge | Payer program | Part D enrollment, bridge eligibility, covered product and presentation, PA. The bridge is time-limited and names Zepbound KwikPen; do not generalize to all tirzepatide or all Medicare patients | Program rules, no GM API observed | Medicare patient | Medicare pays; eligible bridge patient at most $50 per month | Yes | Published terms; GM integration not observed | [PUBLIC https://www.medicare.gov/coverage/weight-loss-drugs] [D:D4.4] |
| H71 | E | LLM provider, vendor unknown, via Promptimus and copilot | Outbound | Prompt context, health records, messages, care-plan draft | API | AI draft or patient chat | GM contract unknown | Yes | Inferred | [F:F3.3] |
| H72 | F | Google OAuth and AWS Cognito, staff plane | Both | Staff identity, extension token | OAuth code flow, /api/internal_oauth |
Admin login | Unknown | No | Observed | [F] |
5. Integration sequence diagrams
5.1 Sign-up and identity
Note: the Segment calls are guarded and were not observed on the GLP-1 redirect path. signup_complete and identify carry email and phone; alias carries only the user ID. The HIE notice and PDF opt-out were observed on the manual about-you form only, not on the Verified review-info path.
5.2 Insurance eligibility
Note: illustrative backend flow. The discovery vendor, clearinghouse protocol and payer response were not observed for this journey.
5.3 Visit, prescription, and pharmacy, cash LillyDirect and insured retail
Note: the cash branch pays the dispensing pharmacy once. Mail order is excluded from GM pay-ahead. 1574056 is GM's observed LillyDirect row; product-level routing may differ.
5.4 Baseline labs via Junction
Note: lab ordering and pharmacy fulfillment are separate flows. If the clinician requires pre-start labs, the pharmacy order waits for result review; otherwise it does not.
5.5 Week-4 check-in and phase change to 5 mg
Note: cash does not route through the PBM. A same-strength refill may already have refills available; a new strength requires an appropriate new prescription.
6. Data, states and events
6.1 Core objects
| Object | Key fields | Owner | States observed | Authority | Evidence |
|---|---|---|---|---|---|
| Patient | id, name, DOB, sex at birth, phone, email, address, consents, attribution, signup_id, signup_sku_id, signup_channel |
Nile-Core | anonymous, authenticated, patient record, blocked, closed | API fields observed; account lifecycle partly inferred | [B:B7] [E:E16] |
| SKU | id, category, state, allows_video_visit, allows_chat, allows_econsult, allows_first_fill, allows_refill, allows_referral, indexable, page_content, component_order |
Catalog | enabled, dark_launched, disabled; pathways draft, published, archived |
Catalog operation inventory | [F:F1] [F:F0.1] |
| SKU option | modality, cash price, insurance price, primary, availability promise |
Catalog | video, chat, econsult, in-person; cash or insurance sub-option | Live API payload | [A:A5.1] |
| Questionnaire | screening id, history id, question order, questionnaire_length, version, edit approval |
Catalog | draft, edit requested, applied, published | Catalog operations; content unrecovered | [F:F2] |
| Question response | questionnaire id, question id, answer, read state | Nile-Core | unanswered, answered, read | API fields | [B:B11] |
| Visit | id, SKU, modality, clinician, scheduled_time, state, meeting_url, billing type, price |
Nile-Core | The client UI classifier maps booked, scheduled, confirmed, awaiting_confirmation, ready_for_visit, held, in_progress, canceled, hold_expired, patient_no_show, plus other care-action strings |
UI classifier; server enum and transitions unverified | [CODE components/CareActions/careActionSection.ts:40-89] |
| Care::Plan | care_id, plan_id, state, next steps, patient_instructions, patient_rationale |
Visitron | The UI classifier maps six preparation strings under care plans: awaiting_curation, awaiting_external_work, awaiting_generation, in_review, awaiting_first_send, awaiting_curation_send. sent is a shared terminal state, not exclusively a plan state |
UI classifier only; server enum and transition order unverified | [E:E1] [CODE components/CareActions/careActionSection.ts:64-78] |
| CarePathway and phase | pathway_id, ordered phases, phase_id, modality, linked SKUs |
Catalog | draft, published, archived | Catalog operation inventory | [E:E1.2] |
| CareJourney criteria | type Lab, Questionnaire, or Visit; status, locked, available_at, deadline, estimated_minutes, lab bundle metadata |
Server-side criteria set | locked, available, completed | Generic criteria API; GLP-1 set unrecovered | [E:E1.2] [E:E6] |
| NextStep and NextStepCard | kind, deadline, assigned_by, snooze, dismiss, due_date, open_to_renew |
Nile-Core | open, snoozed, dismissed, completed | API fields; eight card kinds observed | [E:E5] [E:E9] |
| NextStepReview | proposed_json, final_json, decision, rationale |
Visitron | draft, applied, rejected, confirmed | Operation names recovered; field names dossier-attributed, not first-party contracts | [F:F3.3] |
| Prescription | id, drug, strength, form, quantity, days supply, refills, SIG, pharmacy NCPDP id | DoseSpot and Nile-Core | draft, finalized, transmitted, renewal required | Visitron and DoseSpot operations | [D:D8] |
| PharmacyOrder | id, medication_option_sku_id, NCPDP id, billing_type, cash and insurance price, state, cancel and switch flags |
Nile-Core | client exposes a state string plus cancel and switch flags; four-state sequence is a dossier hypothesis | Cancellation response fields; authoritative enum unverified | [D:D11-D15] [E:E1.3] |
| LabOrder | id, SKUs, network, accession_number, scheduled_at, lab_vendor_name, clinical_fee, result status |
Nile-Core and Junction | received, collecting_sample, sample_with_lab, completed |
API and data model; authoritative enum unverified | [C:C19-C21] |
| Insurance policy | payer, member id, group, network status, copay, onboarding state | Nile-Core | discovered, queued, checked, activated, failed | Context and API fields | [B:B9] |
| Conversation | id, subject category (visit, lab, pharmacy_order), response_expectation, messages, attachments |
Nile-Core and Twilio | open, unread, read, closed | API fields | [E:E3] |
| Payment method | id, brand, last4, expiry, default flag, Stripe token | Stripe | active, deleted, default | Stripe fields | [C:C4.7] |
6.2 State machines that matter
Pharmacy order. The four-state sequence created → pharmacy_selected → order_placed → dispensed is a dossier hypothesis, not an observed authoritative state machine. The inspected client exposes a state string plus can_cancel_pharmacy_order, can_switch_pharmacy, and can_choose_new_pharmacy in a cancellation response. No acknowledgment, rejection, dispense or tracking field was recovered; a server-side feed may exist outside the inspected surfaces. [D:D5.4] [E:E7]
Care plan and next-step review. These are separate objects. The UI classifier contains six care-plan preparation strings plus sent as a shared terminal state. Their membership in a server Care::Plan enum and the transition order are unverified. Visitron exposes review-generation, edit, apply, confirm and reject operations. The proposed_json and final_json field names are dossier-attributed, not recovered first-party contracts. [E:E1] [F:F3.3] [CODE components/CareActions/careActionSection.ts:64-78]
Care journey. Criteria are typed Lab, Questionnaire, or Visit, with locked, available_at, deadline, and status. The recovered API is generic and handles feature-disabled 404s. The GLP-1-specific schedule, blocking rule and exceptions are server-side and were not recovered. [E:E1.2]
Visit. The client UI classifier contains visit-related state strings, including held and hold_expired, plus terminal canceled and patient_no_show. Fee-eligible visit types are video only. The server enum, count and transition rules are unverified. [CODE components/CareActions/careActionSection.ts:40-89]
SKU and pathway. SKUs use enabled and dark_launched; pathways use draft, published, archived. A launch is a Catalog content operation, not a deploy. [F:F0.1]
6.3 Analytics events observed
| Group | Events | Properties worth noting | Evidence |
|---|---|---|---|
| Landing | page, landing_page_loaded, landing_page_frames_dwell, ad_landing_page_view |
path, URL, title, referrer, search, tenant_slug, sku_id, TTFB, DCL, LCP, cache hit, auth flag, frame dwell |
[A:A2] |
| Storefront | sf_viewed_detail_page, new_storefront_pdp_viewed, sf_clicked_sku, sku_page_cta_clicked, new_storefront_request_medication_clicked, sku_page_variant, sku_sticky_cta_variant |
SKU object with price, variant, button type, latency timer | [A:A4] |
| Search | sf_search_start, sf_search_query, sf_submitted_search, sf_viewed_search_results, sf_viewed_search_results_failure |
Raw query and full suggestion array, result count and ids | [A:A11] |
| Signup | signup_page_viewed, signup_referrer, signup_step_phone, signup_step_otp, otp_send_requested, otp_completed, otp_first_digit_entered, otp_resend_requested, otp_submit_attempted, otp_verified, otp_screen_abandoned, signup_complete, merge_identity |
Email and phone in both signup_complete and identify; click ids; signup_channel; OTP telemetry excludes phone and code by rule |
[A:A7] [B:B2] [CODE components/SignupTracker.tsx:16-98] |
| Checkout | visit_id, sku_id, billing_type, insurance_status, price_cents, cancellation_fee_shown, within_24_hours, agreement flags, price_guaranteed, price_fallback |
Funnel render and click events | [C:C8] |
| Care | ns_ namespace, 17 events; PATIENT_RATIONALE_VIEWED, PATIENT_RATIONALE_FEEDBACK, dashboard 1.0 and 1.5 event sets |
Next steps, rationale, dashboard version | [F:F4.1] |
| Insurance | ssi_ namespace; booking_no_medicaid_option, booking_no_availability |
Payer, network, plan category | [F:F6] |
| Experiments | EMAIL_VALIDATION_VARIANT, SKU_PAGE_VARIANT, SKU_STICKY_CTA_VARIANT |
Flag key, anonymous id, Datadog session id | [F:F4] |
| Errors | client_error; Datadog nile-core-api-request |
Method, normalized path, status, latency | [A:A3.1] [F:F4.1] |
Two gaps matter. No event was observed for a pharmacy dispense, a dose taken, a weight measurement, or a PA outcome; production may track these outside the inspected surfaces. And signup_complete and identify both carry email and phone, but both are guarded by tracker mount, fetchUser, analytics availability and a local flag, so firing on the Lilly and GLP-1 CTA path was not observed. [A:A8] [CODE components/SignupTracker.tsx:16-98]
6.4 Where PHI flows
BAA status is unknown for every vendor flow because no BAA inventory was observed.
| Flow | What leaves | Recipient | BAA status | Risk | Evidence |
|---|---|---|---|---|---|
| Browser to Segment | Email, phone, GLP-1 SKU and condition context, raw search queries, click ids | Segment, then unknown destinations | Unknown | High: re-identification plus health interest | [A:H7] [B:H17] [A:A3.4] |
| Browser to Datadog | Recovered replay configuration would capture DOM text, interactions, resources and errors; an explicit phone masking marker was found. Other component rules and effective runtime masking remain unverified; capture of specific GLP-1 questionnaire answers, retention and destination access were not verified | Datadog | Unknown | High-priority privacy review; asserted answer capture is not established | [A:H8] [A:A3.4] [CODE components/Inputs/PhoneInput.tsx:158] |
| Browser to Google Maps | Home address keystrokes, coordinates | Unknown | Medium | [B:H6] [A:H13] |
|
| Browser to Verified | Browser sends phone and DOB to GM; GM then calls Verified. A direct browser-to-Verified call was not observed | Verified | Vendor claims HIPAA, no BAA observed | High | [B:H4] [B:H5] |
| Browser to S3 | Insurance card images, external lab PDFs | AWS | Unknown | High | [B:H12] [C:H8] |
| Nile-Core to Waystar and payer | Eligibility request and response; exact X12 270/271 payload unverified | Waystar, payer | Unknown | High | [B:H8] [B:H9] |
| Nile-Core to Metriport and Particle | Identity, consent, FHIR conditions, meds, allergies, procedures | HIE vendors | Unknown | High | [B:H13] [B:H14] |
| Nile-Core to Slack | Session replay links to #session-replay-new-storefront |
Slack | Unknown | Medium: link access | [A:H23] |
| Nile-Core to Databricks and Metabase | Product and clinical events, dashboards | Internal BI | Internal use; the Metabase login shell is publicly reachable and the reviewed response requires sign-in | Medium: network exposure; unauthenticated data access not established | [E:H17] [F:F4.1] |
| Visitron to Athena and DoseSpot | Encounter, diagnoses, orders and prescriptions; exact payloads unverified | EHR, eRx | Unknown | High | [D:H4] [D:H5] |
| Nabla integration | Status operation recovered; audio/context submission and returned transcript or draft are attributed workflow, not observed payloads. Direction, content and retention require verification | Scribe | Unknown | High | [D:H6] [F] |
| GM to Arrive Health | Patient, drug, pharmacy, benefit context | Arrive | Unknown | High | [D:H7] [E:H4] |
| Patient to Twilio and Zendesk | Phone, SMS and chat content, attachments | Twilio, Zendesk | Unknown | High | [E:H11] [F] |
| GM to LLM provider | Prompt context, health records, messages | Vendor unknown | Unknown | High | [F:F3.3] [E:H16] |
| GM to pharmacy and lab | Prescription, demographics, order, results | Pharmacies, labs | Determine each recipient's role: independent treating provider or business associate. HIPAA minimum necessary does not apply to provider treatment disclosures; assess BAA and data minimization by relationship | Medium: role and contract dependent | [D:H10-H13] [C:H6] [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.502] |
| GM to email provider | Visit links, lab-result notices, prescription notices | Vendor unknown | Unknown | Medium | [E:H15] |
The privacy notice says PHI is handled under BAAs "that General has in place with Emerald Providers" and discloses business associates for technology, transcription, billing, and collection. No subprocessor list or BAA text was found. [F:F8]
7. Money map
7.1 Who pays whom
Capture timing is inferred for visit fees. The checkout shows "Due Today", the cancellation policy says already-paid fees are refunded automatically, and the assignment of benefits allows an up-front estimate, but no charge object or auth-then-capture call was recovered. [C:C4.1]
| Path | Payer | Payee | When | Amount | Basis |
|---|---|---|---|---|---|
| Cash visit | Patient | GM via Stripe | At booking | $100 video, $30 chat | [C:C4.1] |
| Insured visit | Patient | GM or PC at booking | At booking, estimate | $25 estimated copay | [C:C4.1] |
| Insured visit claim | Payer | PC | After claim | Unknown, contract rate | [B:B15] |
| Clinician labor | GM | 1099 clinician | Per completed visit | $50 video or $12 chat for MD; $35 or $8 for NP | [F:F3.4] |
| Lab, cash | Patient | GM via Stripe | At lab checkout | Test price plus $15.00 | [C:C4.3] |
| Lab, wholesale | GM | Lab through Junction | Per order | Unknown | [C:C4] |
| Lab, insured | Payer | Lab | After claim | Unknown; insurance_price null |
[C:C4.3] |
| Drug, cash pre-pay at retail | Patient | GM via Stripe | At pharmacy checkout | Sampled retail $496.12 to $508.09 for the starter KwikPen; $299 is the direct-mail price. Pay-ahead only if offered for the selected pharmacy | [D:D4.3] [LIVE /api/external/pharmacy_comparisons] |
| Drug, retail counter with GM card | Patient | Pharmacy | At pickup | Discounted cash price | [D:D4.3] |
| Drug, mail order | Patient | LillyDirect dispensing pharmacy or Amazon | At pharmacy checkout link | $299, $399, or $449 | [D:D4.3] |
| Drug, insured | Payer | Pharmacy | Claim | Contract rate; patient copay | [D:D4.3] |
| Manufacturer savings | Lilly or Novo | Pharmacy or patient | At adjudication | Reduces patient copay | [D:D4.4] |
| Cancellation fee | Patient | GM | Within 24 hours or no-show | $25 fallback, video only | [C:C4.4] |
| Refund, visit | GM | Patient | After eligible cancellation | Visit fee, 5 to 10 business days | [C:C4.4] |
| Refund, lab | GM | Patient | Request within 6 months of purchase if sample not collected | Full amount, no deduction; collection ends eligibility | [LIVE /refund-policy-labs] |
| Pharmacy routing | Unknown | Unknown | Per fill | No fee or spread field observed | [D:D4.6] |
7.2 Illustrative cash outlay through purchase of the second fill
Assumes a video visit at E0, one Quest Comprehensive GLP-1 panel, the 2.5 mg KwikPen at LillyDirect or Amazon, a week-4 video follow-up, and the 5 mg KwikPen. This is two 28-day drug purchases, not one month of medicine.
| Line | Amount | Evidence |
|---|---|---|
| Initial visit plus first 28-day supply | $399.00 | $100 visit + $299 2.5 mg. [LIVE /api/external/sku_options/300543] [LIVE /api/external/medication_option_skus/710641/cash_price] |
| Initial visit, first supply and Quest panel | $485.58 | Add $86.58. [LIVE /api/external/lab_skus/503263] |
| GLP-1 evaluation, video cash | $100.00 | [LIVE /api/external/sku_options/300543] |
| Comprehensive GLP-1 panel, Quest cash | $86.58 | [LIVE /api/external/lab_skus/503263] |
| Zepbound KwikPen 2.5 mg, 28 days | $299.00 | [LIVE /api/external/medication_option_skus/710641/cash_price] |
| Week-4 follow-up, video cash | $100.00 | [LIVE /api/external/sku_options/300550] |
| Zepbound KwikPen 5 mg, 28 days | $399.00 | [LIVE /api/external/medication_option_skus/710643/cash_price] |
| Two-fill total | $984.58 | Arithmetic on observed prices; calendar timing depends on the journey |
| Same two-fill scenario without panel | $898.00 | [E:E4.5] |
| Same two-fill scenario with chat visits | $844.58 | $30 plus $30 visits |
| Default auto-injector instead of KwikPen | $2,434.76 to $2,486.90 | $1,074.09 or $1,100.16 twice, plus visits and panel; assumes the same unit price on both fills. Re-quote the 5 mg SKU |
| Retail cash instead of direct | $1,278.82 to $1,302.76 | $496.12 or $508.09 twice, plus visits and panel; same assumption |
7.3 Illustrative insured non-drug subtotal
Assumes a commercial plan, in-network video visits at day 0 and week 4, one lab order, and a covered drug after PA. The medication check-in itself may not require a paid visit. Medication copay and lab deductible, coinsurance or uncovered charges are not observable before adjudication.
| Line | Amount | Evidence |
|---|---|---|
| GLP-1 evaluation, video insured | $25.00 estimated | [LIVE /api/external/sku_options/300543] |
| Week-4 follow-up, video insured, if booked | $25.00 estimated | [LIVE /api/external/sku_options/300550] |
| Lab clinical review fee | $15.00, not covered by insurance | [CODE components/Labs/AboutLabPricing.tsx:42-45] |
| Drug liability for both fills | Unknown; insurance.price is null on every GLP-1 medication SKU |
[LIVE medication_option_skus] |
| Lab deductible, coinsurance or uncovered charges | Unknown; insurance_price is null |
[LIVE /api/external/lab_skus/503263] |
| Estimated non-drug subtotal, no paid week-4 visit | $40.00 plus both fills and lab liability | $25 initial visit + $15 lab review; async check-in assumed. Arithmetic on estimates |
| Estimated non-drug subtotal, paid week-4 visit | $65.00 plus both fills and lab liability | Add $25 follow-up. Arithmetic on estimates; final total unknown |
| If PA is denied and the patient pays cash | Add $299.00 and $399.00 | [D:D5.2] |
| If covered commercial and the single-dose pen card applies | As little as $25 per eligible 1-, 2- or 3-month fill, not per month. Caps $100/$200/$300 for those fills, $1,300 per calendar year, up to 13 fills. Card expires 2026-12-31 | [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] |
| If not covered and the single-dose pen card applies | As low as $499 per month for not-covered commercial single-dose pen, subject to current terms | [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] |
| Eligibility boundaries | Government beneficiaries including Medicare, Medicaid, TRICARE and VA are excluded from commercial cards. The prescription must be for an approved use consistent with labeling; off-label use is not an approved use. Secondary claim and actual redemption are not observed | [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] [PUBLIC Zepbound PI §1] |
Note: the KwikPen self-pay ladder is cash-only and excludes insurance reimbursement. A patient cannot combine the $299 KwikPen price with a commercial claim. The insured path and the cash path are mutually exclusive at the fill. [PUBLIC https://zepbound.lilly.com/savings]
7.4 GM revenue lines versus pass-through
| Line | Observed amount | Treatment | Evidence |
|---|---|---|---|
| Visit fee | $100 cash or $25 insured estimate | GM or PC revenue; clinician fee is a variable cost | [C:C4.1] [F:F3.4] |
| Clinician labor | $50 or $35 video, $12 or $8 chat | Variable cost, not revenue | [F:F3.4] |
| Lab clinical review fee | $15.00 per order | Revenue; split with ordering physician unknown | [C:C4.3] |
| Lab test price | $71.58 Quest for 503263 | Pass-through or spread; wholesale cost unknown | [C:C4.3] |
| Platform, order, collection fees | $15.00 to $40.00 platform, $6.00 order, $3.00 to $9.00 collection. Panel 503263 returns $40.00 platform, $6.00 order and $9.00 Quest collection | Returned by API but outside total_cash_price; accounting treatment and whether any is charged are unknown. Do not book as margin or add as a patient charge without settlement evidence |
[F:F5.2] [LIVE /api/external/lab_skus/503263] |
| Drug price | $299, $399, $449 | Manufacturer self-pay price; no GM margin field or contract observed | [D:D4.2] [D:D4.6] |
| Pharmacy routing and GM card | No fee field | Economics unknown | [D:D4.6] |
| Enterprise licensing | Not disclosed | Walmart Better Care Services, Mercy white-label | [F:F5.3] |
The unit-economics read. These are illustrative encounter contributions before other direct costs, assuming the posted contractor fee and full collection. They are not observed GM gross margin, recognized revenue or current provider mix. A cash video visit contributes about $50 with an MD or $65 with an NP before overhead. An insured $25 video visit is negative $25 with an MD and negative $10 with an NP before any payer claim. Chat is the best contribution per clinician dollar: $18 with an MD, $22 with an NP on a $30 cash chat. The employed model implies about $46 to $51 of physician labor per visit at full density. [INFERENCE from observed prices and posted fees] [F:F5.3.1]
Note: evidence-F §5.3.1 models a $25 insured chat row, but the live GLP-1 SKUs offer chat as $30 cash only, with no insurance sub-option. Do not use an insured-chat contribution for this path. [D:D0.3] [LIVE /api/external/sku_options/300543]
8. Operating model
8.1 Roles
| Role | Entity | Tool or queue | What they do on this path | Observed pay and hours | Evidence |
|---|---|---|---|---|---|
| Full-time physician | GM clinical | Athena, Zoom, Zendesk, Slack, Nabla, Visitron | 20-minute video visits, async chat, prescribing, care-plan sign-off | $180k to $200k plus equity and malpractice; 36 clinical hours per week; DEA required | [F:F3.1] [F:F3.4] |
| 1099 physician | GM panel | Same plus Visitron | Video and chat visits alongside another practice | $50 per video, $12 per chat; 10 to 12 hours per week; multistate licensure 20 to 30 percent of US population | [F:F3.4] |
| 1099 nurse practitioner | GM panel | Same | Video and chat visits under collaborative agreements where required | $35 per video, $8 per chat; 12 to 15 hours per week; licensure at least 30 percent of US population | [F:F3.4] |
| Medical Director | Emerald PCs | Visitron, Provider Chat | Clinical oversight, protocol approval, guide review, prompt tuning | Not posted | [D:D3] |
| Clinical operations lead | GM | Cross-portal | Builds clinical teams, policies, partnerships | Not posted | [F:F3.1] |
| Clinician training lead | GM | Training program | Trains every new clinician before first patient | Not posted | [F:F3.1] |
| Care coordinator | GM operations | Athena, phone, Referrals | Scheduling, reminders, calls to patients, provider offices, insurers, labs; referral and authorization paperwork | $22 per hour, full-time, remote | [F:F3.1] |
| Operations Manager and Director | GM operations | Referrals plus internal tools | Line management, referral and scheduling operations | Not posted | [F:F3.1] |
| Manager, NP licensure and collaborative practice | GM | State boards, no internal portal | Maintains CPA templates, collaborating-physician bench, primary-source verification, state filings, pharmacy refusal escalations | Not posted | [F:F3.1] |
| Catalog operator | GM clinical product | Catalog, 106 operations | Authors SKUs, phases, criteria, questionnaires, lab panels, codes, prompts | Not posted | [F:F0.1] |
| Prompt engineer and medical director | GM | Provider Chat, Promptimus, Visitron test harness | Tests prompts, models, temperature; reviews thumbs-down clusters | Not posted | [F:F3.3] |
| RCM Director and VP | GM finance | Waystar, payer portals | Patient access, authorization, coding, billing, denials, collections, payer contracts | Not posted; authorization explicitly in scope | [F:F3.1] |
| Support agent | GM | SMS 98528, Message Center, phones (801) 251-6055 and (801) 255-6051, emails help@generalmedicine.co, hello@generalmedicine.co, support@navhealth.co | Refunds, cancellations, pharmacy and lab questions | Not posted; Mon to Fri 9 to 9 ET, a 12-hour window. Individual clinician shifts are 4 to 6 hours inside it | [C:C3] [F:F3.2] [E:E3] |
| Pharmacist | Partner pharmacy | Pharmacy system | Verify, adjudicate, counsel, dispense, collect | Not posted | [D:D3] |
| Engineering on-call | GM | Datadog, Visitron, Nile-Core | Integration outages, stuck encounters, eRx failures | Not posted | [D:D3] |
Clinicians are contracted or employed by the state PCs or the delegated network and scheduled through Visitron; the MSO employs non-clinical staff and runs the platform. The state-to-PC assignment is server-side and unresolved. [F:F8] [D:D3]
8.2 Queues, tools, SLAs, hours
| Queue | Object | Assignment | Observed SLA or timing | Evidence |
|---|---|---|---|---|
| Visitron appointment list | Appointment | Clinician sees own schedule; no claim primitive | Video promise "today"; chat next slot timestamp | [F:F3.2] |
| Video capacity | Visit | Scheduled block | 20 minutes per visit, max 9 per 4-hour block, 36 clinical hours per week | [F:F3.2] |
| Chat and triage | Chat visit | Zendesk queue | 3-hour response window | [F:F3.2] |
| Draft encounter | Encounter | Clinician owns it | No SLA | [F:F3.2] |
| Async clinical review | Clinician review | Pulled from pending list | Not enabled on the GLP-1 SKU; no SLA. Whether a case is routed manually is unknown | [F:F3.2] |
| Care-plan generation | Care::Plan | Clinician review of AI draft | No system SLA | [F:F3.2] |
| Care Journey criteria | Patient action | Patient-owned, clinician advances phase | Server-side deadlines only | [F:F3.2] |
| Referrals promises | In-person referral | Atomic claim, snooze, drop | Not on the GLP-1 path; allows_referral:false |
[F:F6] |
| Pharmacy order | PharmacyOrder | Patient-driven | No dispense or ack state recovered in the inspected client | [F:F3.2] |
| Message Center | Conversation | Care team by subject | Server-computed per thread; support Mon to Fri 9 to 9 ET | [F:F3.2] |
| Clinician shift | Shift | Clock-out checkout | 4 to 6 hour blocks, Mon to Fri 7 a.m. to 7 p.m. MT | [F:F3.2] |
| Lab result review | LabOrder | Clinician or care team | 48-hour result claim; critical call immediate | [C:C21] [C:C5] |
| PA work | No PA case object recovered in inspected interfaces | RCM and care team | Several business days, no measured p50 or p90; production queue unknown | [D:D5.2] |
| Refund execution | No endpoint | Support, outside recovered tooling | Visit 5 to 10 business days; lab up to 6 months | [C:C3] |
8.3 RACI by activity
R is responsible, A is accountable, C is consulted, I is informed. Every row has exactly one internal accountable role. External pharmacies, labs and payers are counterparties, not accountable owners. This is a proposed operating model, not an observed one.
| Activity | Patient | Eng and Product | Catalog and Growth | Prescribing clinician | Medical Director | NP Licensure | Care Coord and PA | Support | RCM | Privacy and Compliance |
|---|---|---|---|---|---|---|---|---|---|---|
| SEO, sitemaps, default SKU, price copy | I | R | A | I | C | I | I | I | I | I |
| Privacy boundary, replay, Segment PII, BAAs | I | R | C | I | I | I | I | I | I | A |
| Signup, OTP, identity fallback, duplicate charts | R | A | I | C | I | I | I | R | I | C |
| Eligibility, card OCR, self-pay estimate | C | C | I | I | I | I | R | I | A | C |
| State-to-PC routing, license and CPA checks | I | C | I | C | C | A, R | I | I | I | I |
| Screening red flag and acute triage | I | C | C | R | A | I | C | I | I | C |
| Visit, indication, medication reconciliation, counseling | C | I | I | A, R | C | I | I | I | I | I |
| eRx signing, presentation, quantity, supplies | I | C | I | A, R | I | I | I | I | I | I |
| Labs, abnormal and critical result loop | R | C | I | A, R | C | I | R | I | I | I |
| Pharmacy selection, eRx ack, stockout reroute | R | C | I | C | I | I | A, R | C | I | I |
| PA submission, RFI, appeal, claim re-adjudication | I | C | I | C | I | I | R | I | A | I |
| Possession, cold chain, Dose-1 training | R | C | I | C | A | I | R | C | I | I |
| Weeks 1 to 3 side effects and safety report | I | C | I | R | A | I | C | I | I | C |
| T+14 to T+18 refill start and T+28 continuity | R | C | I | A, R | C | I | R | I | I | I |
| Refunds and cancellation waiver | I | C | I | I | I | I | I | R | A | C |
| Records access, export and retention | I | C | I | I | I | I | I | R | I | A |
8.4 Staffing: known versus unknown
Known:
- About 104 employees, three hubs, 16 open roles: 4 clinical, 2 operations, 4 engineering, 3 product, 3 finance. [F:F9]
- 1099 clinician pay and hours; care coordinator at $22 per hour; FT physician at $180k to $200k for 36 clinical hours. [F:F3.4]
- 20 public clinician bios. [F:F9]
Unknown:
- Headcount for care coordination, support, RCM, and pharmacy or PA. No pharmacy technician, prior-auth specialist, or benefits-verification role appears among the 16 open requisitions. [F:F9]
- Queue depths, arrival rates, and p50 or p90 turnaround for any queue.
- After-hours clinical coverage. The only emergency instruction is 911; no nurse line or on-call clinician pager was observed. [E:E16]
- Whether Zendesk also backs patient support agents or only clinician chat. [F:F3.2]
- BAA inventory and subprocessor list. [F:F8]
9. Failure modes and branches
| Trigger | Patient impact | Current handling observed | Gap | Recommended control | Evidence |
|---|---|---|---|---|---|
| Commercial head terms do not rank | Patient never finds GM | None | SEO architecture sends crawlers to noindex /s/ URLs |
Fix canonical, sitemap, and internal links to /dp/ |
[A:A2.2] |
/weight-loss short URL |
Patient hits a login wall | 307 to /login |
Not in sitemap or internal links | Redirect to /store/weight-loss or /get-started |
[A:A8] |
| Default Zepbound SKU is the auto-injector | Price shock at $1,074.09 versus $299 | Family default and Lilly CTA point at the expensive form; production intent unverified | Price and default mismatch | Default to KwikPen or show a form comparison with prices | [A:A5.1] [D:D0.3] |
| Vial SKU selected | No price, no direct channel | Shows "-" and "priced after visit" | Null cash price, no LillyDirect row | Hide or price the vial path | [A:A5.2] [D:D0.3] |
| Public catalog does not quote insured drug cost | Drop-off at the visit fee | "Available after visit" tooltip; RTPB may estimate after prescribing | No pre-visit patient-specific estimate | Show a range and explain that the adjudicated claim sets the payable amount | [A:A5.2] [CODE components/ProductDetailPage/MedicationPriceCard.tsx:12-20] |
| OTP not delivered | Signup blocked | Resend, support short code | No voice or email fallback observed | Add fallback channel and a delivery-failure queue | [B:§5] |
| Verified lookup misses | Silent manual form | dob_lookup_failed, cookies cleared |
No explanation to the patient | Explain the fallback and why it happened | [B:§5] [LIVE-SRC useVerifyIdentitySignupFlow.ts:151-174] |
| Under 18 | Blocked | Client-side message | Correct behavior | Keep | [B:§5] |
| Territory address | Cannot complete about-you | State list is 50 plus DC only | No territory options | Add territories or state the service area | [B:§5] |
| Insurance not found | Self-pay at $100 | Try another or continue without insurance | No benefits escalation queue recovered | Add a benefits specialist queue | [B:§5] [C:C4] |
| Eligibility timeout | Uncertain price | Copy allows up to 60 seconds | No client timeout branch recovered | Add timeout, retry, and save-and-resume | [B:§5] [C:C4] |
| HIE returns nothing | Manual history entry | Four-step wizard | No records coordinator observed | Add a records chase queue with a 1 business day target | [B:§5] |
| Questionnaire red flag | Off-ramp | Care team text, different SKU, unavailable screen | No queue or SLA recovered | Clinical triage queue with severity routing | [B:§5] |
| No clinician licensed in state | No slots | booking_no_availability event |
No waitlist observed | Waitlist and state expansion signal | [B:§5] [C:C5] |
| No-show or late cancel | Fee charged | Card on file; Medicaid exempt; reschedule free | Fee amount unpublished | Publish the fee and show it at booking | [C:C4.4] |
| Payment fails | Cannot book | Toast, stay on form | No retry automation observed | Dunning and save-and-resume | [B:§5] |
| PA required | Wait of several days | RTPB flag, manual follow-up | No dedicated PA case or submission contract recovered; staff may work in payer portals or other tools | PA case object with status, owner, and deadline | [D:D5.2] |
| PA denied | Cash, switch, or abandon | Manual, marketing claims follow-through | No appeal workflow recovered | Denial and appeal queue with reason codes | [D:D5.2] |
| eRx never reaches pharmacy | No drug, patient calls | No ack or dispense state recovered; cancel and reroute | Patient may be the error detector; production may have a feed | Dispense and rejection feed, exception queue | [E:E16] [E:E1.3] |
| Out of stock | Delay | Compare drawer and switch flags | No inventory signal in inspected feed | Stock check and automatic reroute | [D:D5.3] |
| Claim rejected at counter | Patient pays cash or waits | No claim state recovered in the inspected GM interfaces; production state unknown | No rejection feed recovered; production integration unknown | Claim status integration | [D:D5.3] |
| Mail-order checkout link missed | No drug | Pharmacy follow-up described; GM action unverified | No GM visibility observed | Status feed and outreach task | [D:D5.3] [D:D16] |
| Cold-chain excursion | Product compromised | Pharmacy replacement | No GM tracking or temperature telemetry recovered; production handling unknown | Patient report flow and replacement case | [D:D5.3] |
| Dose escalation needs a new PA | Delay past T+28 | None observed | No new-strength pre-check recovered; configured workflow unknown | Check PA scope before the week-4 decision | [E:E5] [E:E8] |
| 45-day offer lapse, 7.5 to 15 mg only | Price may rise from the offer price | No price-window reminder in inspected client | Condition runs from delivery or receipt of the previous fill, not purchase date | Remind from the recorded receipt date; do not apply to 2.5 or 5 mg | [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] |
| Check-in not completed | Renewal may be affected | criteria_deadline and card |
The GLP-1 blocking rule and exception owner are unverified; same-strength refills depend on prescription, pharmacy and payer | Verify the configured pathway rule before displaying a hard block | [E:E5] [E:E6] |
| Severe side effect after hours | No GM clinical response path recovered; production handling unknown | 911 instruction observed; GM after-hours clinical route not recovered | No nurse line or on-call clinician observed | After-hours triage line and escalation playbook | [E:E16] |
| Patient stops treatment | No record, no transition in inspected client | No complete stop workflow recovered; production handling unknown | No distinct stop state recovered | Stop and transition flow with records and billing | [E:E11] |
| Replay or analytics leak | Privacy exposure risk | No consent gate observed; replay default allow | Specific GLP-1 capture, runtime masking, retention and destination access unverified | Consent management, masking, and vendor BAA review | [A:A3.4] |
| Billing literals differ from the reconstructed spec | Wrong charge or no charge risk | Client checks gm_card and pharmacy_delegated; reconstructed spec uses cash and pharmacy_delegation |
Authoritative server BillingType unverified |
One schema, contract tests, and reconciliation | [D:D5.4] |
| State-to-entity mapping unverified | Wrong entity or consent risk | Server-side practiceId filter |
Legal addresses and NPPES jurisdictions differ; not proof of a defect | Publish and test a state-to-entity matrix | [D:D5.4] |
| Metabase login shell is publicly reachable | Network exposure risk | Sign-in page observed; data access not established | SSO configuration and permissions require review | SSO, network restriction, and audit | [F:F4.1] |
| No good-faith estimate for self-pay | Patient cannot see an itemized expected cost | Per-SKU prices and checkout totals in inspected surfaces; no estimate artifact recovered | No GFE artifact or delivery flow recovered | Add a GFE queue: 1 business day for 3 to 9 business days ahead, 3 business days for 10 or more ahead or a pre-scheduling request | [PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate] |
| No accessibility or interpreter path | Patient cannot complete intake or the visit | None observed | No accommodation queue, captions or interpreter workflow observed | Add an access-needs field and a staffed accommodation queue | [INFERENCE: common practice] |
| Pen needles not observed in the catalog | Patient may not be able to inject a KwikPen | Label and pharmacy counseling; pharmacy may supply or co-dispense | No needle or sharps SKU observed, no supply check | Add a supply bundle or a required counseling step at first fill | [E:E2] [E:§6 q14] |
| Carrier scan treated as possession | Wrong address, damage, or temperature excursion goes unnoticed | Pharmacy-side tracking described; GM visibility unverified | No patient possession confirmation observed | Ask for possession confirmation and route exceptions to the pharmacist | [INFERENCE: common practice] [D:D17] |
| No contraception counseling field | Label counseling requirement can be missed at start and at escalation | Clinician judgment; care may occur without a structured field | No structured field or reminder observed | Add counseling and a 4-week backup-method reminder to the visit and week-4 criteria | [PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §8.1] [D:D6] |
| No T0 administration record | Refill clock may be anchored to payment or shipping | No administration endpoint observed | Possession, administration, delayed start and decline are not distinguished | Ask for patient-reported T0 or retain start unknown; never infer from claim or delivery | [INFERENCE: proposed control] |
| PA approval not linked to claim | Approval may not produce a paid or dispensed fill | No re-adjudication object observed | Approval scope, expiry and claim result are not carried together | Record approval scope and require pharmacy re-adjudication before promising a fill | [D:D5.3] [INFERENCE: common practice] |
| Product-specific safety review not evidenced | Contraindication and warning handling may be inconsistent | Clinician judgment; no structured field observed | Source version, finding, decision and advice are not captured together | Add a structured safety review and escalation owner | [PUBLIC Zepbound PI §§4-5, 7-8] |
10. Technology plan inputs
10.1 Systems and integrations
| Capability | Current state observed | Build, buy, or partner | Data contract needed | Gap to avoid or fix | Evidence |
|---|---|---|---|---|---|
| Patient identity and session | Cognito with phone OTP through Twilio; Google SSO in code but not live | Buy | Phone, OTP challenge, session, isExistingUser, tenant |
Add email or voice fallback; define duplicate-account and phone-reuse rules | [B:H2] [B:H3] |
| Identity autofill | Verified 1-Click Signup after phone and DOB | Buy | Request: phone and DOB; response: name, sex, email, addresses, confidence | No error surfaced on miss; log and explain the fallback | [B:H4] |
| Identity proofing | Persona wired for in-person and a generic pre-visit requirement; GLP-1 trigger unknown | Buy | Inquiry id, document type, liveness result, manual attestation | Define which GLP-1 cases require KYC and who can attest | [B:H22] |
| Insurance discovery | Verified candidate plus payer directory and card OCR | Buy or partner | Payer, member id, group, plan, network, copay, deductible | One source of truth; timeout and retry semantics | [B:H5] [B:H8] [B:H11] |
| Eligibility and claims | Waystar inferred from hosts; no payload observed | Buy | X12 270 and 271, error codes, payer ids, service types | Add idempotency, audit trail, and a benefits exception queue | [B:H8] [C:H11] |
| HIE | Metriport primary, Particle secondary | Buy | FHIR Condition, MedicationStatement, AllergyIntolerance, Procedure; consent; source tag | Provenance and freshness required; no silent empty chart. Privacy and compliance must verify notice version, applicable disclosure or authorization basis and opt-out status on both Verified and manual signup branches before HIE retrieval. Carry source, timestamp and effective opt-out status into chart and AI prewarm; honor the published opt-out. Missing or conflicting evidence routes to privacy review and manual history, not presumed permission. Production enforcement unverified | [B:H13] [B:H14] [PUBLIC https://generalmedicine.co/hipaa-privacy-practices] |
| Scheduling and visits | Nile-Core plus Visitron; 20-minute slots, 9 per 4-hour block | Build | Visit id, SKU, modality, state, clinician, location state, price | Add a claim or assignee primitive to review queues | [F:F3.2] [DATA internal_portals_recon.json → visitron.rtk_endpoints] |
| Video | Zoom link by SMS and email | Buy | Meeting URL, id, passcode, join status | No attendance or connection-failure event observed | [E:H12] [C:C8] |
| eRx | DoseSpot SSO and NCPDP SCRIPT to NCPDP id | Buy | Rx payload, NCPDP id, refills, SIG, days supply, cancel and replace | Single point of failure; needs outage playbook and fallback | [D:H5] [F:F3.1] |
| Benefit check | Arrive Health RTPB plus DoseSpot RTPB | Buy | Patient, drug, NDC, pharmacy, copay, formulary, PA flag, inquiry id | No PA submission or appeal object recovered; production workflow unknown | [D:H7] |
| EHR of record | Athenahealth sync and resync | Buy | Encounter, diagnoses, orders, care plan, athena_id |
Resync failures need a queue and reconciliation | [D:H4] |
| Ambient scribe | Nabla status and note draft | Buy | Audio, transcript, note draft, status | Define retention and consent for audio | [D:H6] |
| Care plan and next steps | Care::Plan plus AI draft and clinician sign-off |
Build | proposed_json, final_json, rationale, state, next-step cards |
Prompt version and model must be recorded per output | [E:E1] [F:F3.3] |
| Patient copilot | /ai with Metriport prewarm and Braintrust feedback |
Build plus partner | Consent, context, messages, feedback, model version | Clinical guardrails, escalation, and PHI handling unproven | [E:E13] [F:F3.3] |
| Pharmacy directory | Live REST feed with NCPDP ids, prices, distance, fulfillment_owner |
Build aggregator plus partner feeds | NCPDP id, chain, price, distance, fulfillment owner | No in_stock, hours, city, state, or tracking |
[D:D12] [A:H15] |
| Pharmacy order | Four-state chain is a dossier hypothesis; client exposes a state string plus flags | Build | Order id, NCPDP id, billing type, price, state, flags | No dispense, ack, reject or tracking field recovered; production feed unknown | [D:D11-D15] [E:E1.3] |
| Mail-order handoff | eRx to LillyDirect, Amazon, NovoCare; patient pays the pharmacy | Partner | Rx, patient, NCPDP id, checkout status, ship status | No return-status contract recovered; verify existing pharmacy feeds and staff workflows before building another integration | [D:H10] [D:H11] |
| Retail handoff | eRx plus NCPDP claim; prepaid card or GM card | Partner | Rx, claim, copay, rejection, dispense | No claim-rejection or dispense state recovered; production integration unknown | [D:H13] |
| Inventory and substitution | No inventory signal in the inspected comparison feed; production stock feeds unknown | Buy or partner | NDC, strength, quantity on hand, backorder, ETA | Add stock check before promising a fill date | [D:D5.3] |
| Payments | Stripe SetupIntent, payment method, charge, 3DS | Buy | Payment method id, amount, status, refund, idempotency key | Visit charge capture timing inferred, not observed | [C:H1] |
| GM card and discount switch | BIN, PCN, group, member id | Partner, sponsor unknown | Card identity, eligibility, claim routing, remittance | Two instruments share one name; model separately | [D:D4.3] [C:H14] |
| Good-faith estimate | No compliant estimate artifact recovered; per-SKU prices only | Build | Trigger, self-pay status, issuing entity, dated itemization, delivery evidence, dispute reference | Deliver within 1 business day for 3 to 9 business days ahead, within 3 business days for 10 or more ahead or a pre-scheduling request | [PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate] |
| Identity assurance policy | OTP plus Verified autofill or manual fallback; Persona trigger unknown | Build plus partner | Accepted evidence, risk trigger, verification method, verifier, time, duplicate-chart resolution | Define before prescribing; do not equate autofill with proofing | [B:H4] [B:H22] |
| Manufacturer savings and COB | No field or workflow recovered | Build or partner | Program and version, approved use, government exclusion, primary claim, secondary claim, caps, expiry, accepted price | Eligibility and redemption unverified; model separately from GM card | [D:D4.4] [PUBLIC https://zepbound.lilly.com/savings/terms-and-conditions] |
| Labs | Junction and Vital; Quest, Labcorp, BioReference | Buy | Order, requisition, accession, result, critical flag, PDF | Fee components outside total; delegated-flow mode unknown | [C:H5] [C:H6] |
| Lab results | Dashboard, Updates, PDF, abnormal_results_count |
Build plus partner | Result status, reference range, interpretation, critical call | No patient-facing critical-result SLA | [C:C21] |
| Messaging | Twilio Conversations and SMS 98528; Message Center behind a flag | Buy | Conversation id, subject, response_expectation, attachments |
Support and clinical messaging overlap; one owner needed | [E:H11] [F:F3.2] |
| Unidentified vendor | Buy | Template, event, delivery status | Vendor and BAA unknown | [E:H15] |
|
| Product analytics | Segment through a first-party proxy | Buy | Event schema, identity resolution, consent, destination list | No complete analytics schema or consent-enforcement mechanism recovered; email and phone appear in guarded client calls. Backend governance and runtime sending remain unverified | [A:H7] |
| Replay and monitoring | Datadog RUM and Logs at 100 percent | Buy | Session, user id, redaction rules | Explicit phone masking marker found; other component masking and runtime behavior unverified | [A:H8] |
| Feature flags | LaunchDarkly with reporting | Buy | Context key, flag version, evaluation | Flag state mirrored to Datadog, useful for audit | [A:H9] |
| Warehouse and BI | Databricks plus Metabase 1.63.10; the login shell is public and requires sign-in | Build and operate | Table contracts, lineage, access policy | Network exposure requires review; unauthenticated data access not established | [F:F4.1] |
| Prior authorization | No dedicated PA case, submission or appeal contract recovered in the inspected client or portal inventories; staff may use payer portals or other tools | Build or partner | Case id, payer, drug, NDC, criteria, evidence, status, deadline, appeal | Highest operating gap on the insured path | [D:D5.2] |
| Dose and adherence | No dose-administration event recovered in the inspected client surfaces; production may record this elsewhere | Build | Dose event, device, site, timestamp, missed-dose reason | Cannot distinguish stable from stopped from the inspected data | [E:E4] |
| Weight and vitals | Only typed into questionnaires or recorded at visits in the inspected surfaces; production device sync unknown | Build or partner | Measurement, date, source, unit | No device integration observed | [E:E12] |
| Catalog and pathways | Catalog with 106 operations, one cache tag | Build | SKU, option, phase, criteria, questionnaire, codes, lab panel | Add approval workflow beyond questionnaires and pathways | [F:F0.1] |
| Refunds | No refund endpoint in the inspected public or internal API inventories; execution may use Stripe or back-office tools | Build or partner | Order id, payment id, reason, amount, status | Refund execution system unverified | [C:C3] |
10.2 Data contracts and identifiers
The journey needs a crosswalk, not one global identifier. Each boundary must carry enough to reconcile:
| Boundary | Identifier | Required fields | Failure semantics | Status | Evidence |
|---|---|---|---|---|---|
| Patient record | patient_id, signup_id |
Phone, DOB, name, address, consents, tenant | Duplicate match, phone reuse, partial record | Observed | [B:B7] |
| Visit | visit_id |
SKU, modality, clinician, state, price, billing type | Hold expiry, no-show, reschedule | Mixed; enum unverified | [F:F3.2] |
| Questionnaire | questionnaire_id, response_id |
Version, question id, answer, submitted at | Partial submission, edited version | Observed fields; content unrecovered | [B:B11] |
| Prescription | prescription_id, care_action_prescription_id |
Drug, NDC, strength, form, quantity, days supply, refills, NCPDP id | Finalize failure, cancel, replace | Observed | [D:D8] |
| Pharmacy order | pharmacy_order_id |
NCPDP id, billing type, price, state, payment id | Ack timeout, reject, dispense, cancel | Mixed; state model proposed | [D:D11-D15] |
| Lab order | lab_order_id, accession_number |
Panel, network, fee, collection status, result | No-show, redraw, critical value | Mixed; enum unverified | [C:C19-C21] |
| Payment | payment_method_id, payment_intent_id |
Amount, currency, status, refund, idempotency key | 3DS required, declined, duplicate charge | Observed | [C:C7] |
| PA case | pa_case_id, payer case number |
Drug, NDC, criteria, evidence, status, deadline | Missing information, denial, appeal | Proposed | [D:D5.2] |
| Conversation | conversation_id |
Subject, participant, response_expectation, attachments |
Delivery failure, after-hours | Observed | [E:E3] |
| Shipment | Carrier tracking id | Order id, address, ship date, exception | Lost, delayed, temperature excursion | Proposed | [D:D17] |
| Dose event | dose_event_id |
Prescription and fill id, status, scheduled and administered time, source, reason | Never started, missed, delayed, declined, unknown | Proposed | [INFERENCE: common practice] |
No recovered contract covers a pharmacy acknowledgment and dispense event, a PA case, or a dose-administration event. The shapes below are proposed, not implemented. Each needs a version, timestamp semantics, idempotency key, source of truth, reconciliation owner, and a verified producer-consumer pair.
type PharmacyBillingType =
| "cash_prepaid_retail"
| "gm_discount_card_retail"
| "direct_mail_cash"
| "commercial_insurance"
| "government_insurance";
interface PharmacyOrderContract {
pharmacy_order_id: string;
prescription_id: string;
patient_id: string;
medication_option_sku_id: string;
ndc11: string;
presentation: "kwikpen_multidose" | "autoinjector_singledose" | "vial_singledose" | "vial_multidose";
strength_mg: 2.5 | 5 | 7.5 | 10 | 12.5 | 15;
package_count: number;
doses_per_package: number;
dose_volume_ml: number;
concentration_mg_ml: number;
total_volume_ml: number;
days_supply: 28;
companion_supplies: { pen_needles: boolean; syringes: boolean; sharps_container: boolean };
ncpdp_provider_id: string;
billing_type: PharmacyBillingType;
transmission_state: "created" | "pharmacy_selected" | "erx_transmitted" | "erx_acknowledged" | "erx_error_or_clarification";
claim_state: "not_submitted" | "adjudicating" | "rejected_pa_required" | "rejected_other" | "paid" | "reversed";
dispense_state: "not_dispensed" | "ready" | "dispensed" | "partially_dispensed" | "canceled";
shipment_state?: "not_shipped" | "shipped_cold_chain" | "carrier_delivered";
possession_state: "unknown" | "confirmed" | "not_received" | "wrong_item" | "damaged";
exception_state?: "none" | "temperature_reported" | "product_complaint" | "open";
dispensed_at?: string;
carrier_delivered_at?: string;
possession_confirmed_at?: string;
idempotency_key: string;
updated_at: string;
}
interface PriorAuthCaseContract {
pa_case_id: string;
patient_id: string;
prescription_id: string;
pharmacy_order_id?: string;
payer_id: string;
raw_reject_code?: string;
reject_code_set_id?: string;
reject_code_set_version?: string;
classification_version?: string;
classified_reject_reason?: "pa_required" | "plan_exclusion" | "plan_limitation" | "dur" | "other";
submission_channel: "epa" | "payer_portal" | "fax" | "unknown";
external_case_number?: string;
submission_receipt?: string;
submitted_evidence_versions?: string[];
payer_message?: string;
indication: "obesity_bmi_30" | "overweight_bmi_27_comorbidity" | "osa_obesity" | "t2d";
baseline_bmi?: { value: number; measured_at: string; source: "intake" | "hie" | "visit" };
status: "open" | "submitted" | "rfi_pending" | "approved" | "denied" | "appeal_submitted" | "appeal_decided" | "cash_fallback" | "closed_abandoned";
submitted_at?: string;
rfi_due_at?: string;
rfi_history?: Array<{
request: string;
received_at: string;
due_at: string;
owner: string;
response_evidence_versions: string[];
response_sent_at?: string;
response_receipt?: string;
}>;
approved_scope?: {
auth_number: string;
product_ndc: string;
presentation: string;
strengths: string[];
quantity: number;
days_supply: number;
effective_from: string;
expires_at: string;
};
denial_reason?: string;
appeal_deadline?: string;
appeal_decision?: string;
claim_result?: "paid" | "rejected" | "reversed" | "not_reprocessed";
final_claim_ref?: string;
abandonment_evidence_ref?: string;
pharmacy_reprocessed_at?: string;
linked_dispense_or_reversal?: string;
closure_reason?: string;
sla_due_at: string;
}
type DoseEventStatus = "planned" | "administered" | "missed" | "delayed" | "declined" | "unknown";
interface DoseEventBase {
dose_event_id: string;
patient_id: string;
prescription_id: string;
fill_id: string;
reported_at: string;
source: "patient_reported" | "clinician_recorded" | "device";
reason?: string;
injection_site?: "abdomen" | "thigh" | "upper_arm_caregiver";
contraception_backup_counseled: boolean;
}
type DoseEventContract = DoseEventBase & (
| { status: "administered"; administered_at: string; scheduled_at?: string }
| { status: "planned" | "missed" | "delayed" | "declined" | "unknown"; administered_at?: never; scheduled_at?: string }
);
Invariant: for administered status, administered_at is required; scheduled_at is optional. For planned, missed, delayed, declined or unknown status, administered_at is absent and scheduled_at is optional when the schedule is unknown. Derive T0 only from an accepted administered event with a timestamp and source, never from scheduled_at, possession or shipment. Validate at ingestion.
PA invariant: do not mark an RFI satisfied or a case successfully closed without its receiving and closure evidence. Preserve the payer message, reject_code_set_id and reject_code_set_version separately from classification_version. A PA approval covers only the product, NDC, presentation, quantity and days supply recorded in approved_scope; do not assume it covers another presentation because a strength matches. Close a case only with final_claim_ref or abandonment_evidence_ref plus closure_reason.
10.3 Implementation gaps a builder should avoid
- Do not default a drug family to its most expensive presentation. Make price part of the default selection logic.
- Do not put indexable pages outside the sitemap and noindex pages inside it.
- Do not send email, phone, and condition context to a product analytics tool without a BAA and a consent basis.
- Do not initialize 100 percent session replay with
defaultPrivacyLevel: allowon routes that may render clinical intake or PHI. Enforce mask-user-input, gate replay on consent, and verify the actual clinical surfaces before launch.[A:A3.4] - Do not name two different payment instruments "card". A prepaid payment card and a discount BIN are separate objects.
- Do not let client and server enums drift. Generate both from one schema.
- Do not model a pharmacy order without an acknowledgment, rejection, and dispense state.
- Do not render a claim of "we handle prior authorization" without a PA object, owner, and SLA behind it.
- Do not calculate prescription quantity from a field whose unit is ambiguous.
- Do not expose a BI tool without authentication, even on a staging host.
- Do not launch a state without a signed state-to-professional-entity matrix.
- Do not treat a session cookie with a 30-minute life as durable SKU attribution for a high-consideration purchase.
11. Operating plan inputs
11.1 Queues to stand up
| Queue | Trigger | Owner | Proposed target, design not observed | Volume driver | Evidence |
|---|---|---|---|---|---|
| Identity exception | OTP failure, Verified miss, under-18, territory address | Support | 1 business day | Signup attempts | [B:§5] |
| Benefits and eligibility | Not found, timeout, multiple plans, out of network | Care coordinator or benefits specialist | 1 business day | Insured bookings | [B:§5] [C:C4] |
| Clinical intake red flag | Questionnaire off-ramp: emergency, urgent, high_risk, requires_triage, unable_to_treat, different_sku |
Licensed clinician | Emergency immediate; urgent prompt triage; high risk or requires triage before booking; unable to treat with alternate disposition; different SKU by clinical approval | Screening completions | [B:B11] [CODE lib/analytics/questionnaireInterstitialAnalytics.ts:3-9] |
| No availability | No licensed clinician in state | Operations | Same day response with waitlist | State supply | [B:§5] [C:C5] |
| No-show and late cancel | Visit state transition | Care coordinator | 1 business day outreach | Booked visits | [C:C4.4] |
| PA new request | RTPB flag or pharmacy rejection | PA specialist plus prescriber | 1 business day to open, daily follow-up | Insured fills | [D:D5.2] |
| PA denial and appeal | Payer denial | RCM plus prescriber | Notify patient 1 business day, appeal within plan deadline | Insured fills | [D:D5.2] |
| Pharmacy transmission failure | No acknowledgment within 1 business day | Pharmacy liaison | Same day resend or reroute | All fills | [E:E16] |
| Out of stock and reroute | Pharmacy reports stockout | Pharmacy liaison | Same day alternative | All fills | [D:D5.3] |
| Lab collection overdue | Order not collected in 5 days | Lab navigator | 1 to 2 business days outreach | Lab orders | [C:C20] |
| Lab abnormal or critical | Result flag or critical webhook | Clinician | Critical immediate, routine 1 business day | Lab orders | [C:C21] |
| Week-4 check-in incomplete | Criteria deadline near | Care coordinator | 3 business days before deadline | Active patients | [E:E6] |
| After-hours symptom | Message or call outside shift | Clinical triage | Immediate emergency direction. Suspected pancreatitis: stop tirzepatide and arrange immediate clinician contact or urgent assessment, not a next-shift reply | Active patients | [PUBLIC Zepbound PI §5.5] [E:E16] |
| Refund and billing | Request or policy eligibility | Support and RCM | 1 business day acknowledgment | All payments | [C:C4.4] |
| Records request | Patient request or transfer | Privacy officer | Statutory deadline, commonly 30 days | All patients | [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.524] |
| Good-faith estimate request | Self-pay or uninsured patient requests or schedules applicable care | Billing and compliance | 3 to 9 business days ahead: within 1 business day. 10 or more business days ahead, or requested before scheduling: within 3 business days | Self-pay bookings | [PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate] |
| Adverse event and product complaint | Reported side effect, product defect, damage or temperature issue | Licensed clinician plus Medical Director | Urgent care first; separate reporting review and product-complaint follow-up | Active patients and fills | [PUBLIC Zepbound PI §17] |
| Possession, training or start delay | Possession or training unresolved at the agreed follow-up time, or no reported actual start three calendar days after the patient-reported planned start date. If the planned start is unknown, open a coordination task on confirmed possession; never compute an overdue threshold from an absent T0 | Care coordinator and pharmacist | 1 business day outreach after the defined trigger | Every fill | [INFERENCE: proposed queue] |
| Dose continuity risk | Pen supply ends before next fill is in hand | Care coordinator and PA lead | Same day escalation and reroute | Active patients | [E:E5] [INFERENCE: proposed queue] |
| Identity, credential or authority exception | Duplicate chart, manual-entry mismatch, expired license, travel, no eligible clinician, pharmacy refusal | Compliance and clinical operations | Hold unsupported care; same-day routing to licensed reviewer | Signup and booking | [PUBLIC https://www.mbc.ca.gov/Resources/Medical-Resources/telehealth.aspx] |
Proposed queue contract: record the workflow, patient and trigger-event case key, system of record, intake time, accepting role, acceptance time, next-update due time, escalation and evidence-backed closure. Routine targets use staffed business hours, explicitly scheduled in America/New_York; urgent clinical intake and safety cases require a staffed 24/7 accepting clinical service and backup. If that service is not provisioned, do not promise an immediate GM response: provide the approved external urgent or emergency route. Close only with documented receiving acknowledgment and disposition, not message delivery. Operations must populate hours, backup and workflow-specific closure evidence for every row and obtain clinical and compliance approval before publishing a service target. "Immediate," "same day" and "one business day" are design targets, not observed GM service contracts.
| Off-ramp value | Proposed action | Owner |
|---|---|---|
emergency |
Immediate emergency-services direction and urgent handoff | Licensed clinician |
urgent |
Prompt licensed triage before any booking or prescribing | Licensed clinician |
high_risk or requires_triage |
Clinician review before checkout or prescribing proceeds | Licensed clinician |
unable_to_treat |
Explicit explanation and alternate-care or referral disposition | Clinician and care coordinator |
different_sku |
Clinician-approved alternate pathway preserving relevant answers and provenance | Clinician and catalog |
11.2 Staffing drivers
- Video capacity: 20 minutes per visit, 9 per 4-hour block, 36 clinical hours per week for a full-time physician. That is 81 visits per week at full density or 3,888 per year across 48 working weeks. This is a capacity ceiling, not staffed capacity.
[F:F3.4] - Chat capacity: a 3-hour response window, with chat shifts extended when the queue is long.
[F:F3.2] - Care coordination: one coordinator per unknown number of active patients. The only observed cost is $22 per hour.
[F:F3.4] - PA and pharmacy liaison: no such role or queue appears in the 16 open requisitions or inspected portal inventories; production staffing unknown. Staff this from measured arrivals and handling time, not from the org chart.
- Clinical review at week 4: one review per active patient per month while titrating, then roughly every three months.
[LIVE GLP-1 guide] - Lab follow-up: one result review per order, with outreach only on abnormal results.
[C:C21]
| Illustrative workload per 1,000 new starts and 1,000 month-2 renewals | Assumption | Hours per month | FTE at 144 productive hours | Basis |
|---|---|---|---|---|
| Video visits | 70 percent of 1,000 initial encounters are video; independently assume 35 percent of 1,000 renewal reviews need video: 700 initial plus 350 renewal at 26.7 minutes | 467.3 | 3.2 | [F:F3.4] [INFERENCE: planning assumption] |
| Chat and async reviews | 300 initial chats plus 650 check-in reviews plus 250 lab or side-effect reviews at about 10 minutes | 200 | 1.4 | [F:F3.4] [E:E7] |
| PA and pharmacy liaison | 500 initial PA checks plus 250 step-up checks at 25 minutes, plus 300 follow-ups at 10 minutes | 362.5 | 2.5 | [F:F3.4] [D:D5.2-D5.3] |
| Support and lab navigation | 400 support contacts at 10 minutes plus 600 lab follow-ups at 5 minutes | 116.7 | 0.8 | [F:F3.4] [C:C3] |
| Total before coverage | Sum of the rows | 1,146.4 | 8.0 | [INFERENCE: arithmetic] |
These are illustrative planning assumptions, not observed volumes, arrival rates, handling times or productivity. The 144 productive hours per FTE, 26.7-minute video assumption and 10/25-minute handling times are model inputs. Add coverage, leave, shrinkage and arrival variability before deciding headcount.
11.3 Scripts and playbooks
| Situation | Playbook content |
|---|---|
| Price explanation | Separate visit fee, lab fee and drug price. The public catalog does not quote this patient's insured drug cost; after prescribing, RTPB may produce an estimate, and the pharmacy's adjudicated claim sets the payable amount. |
| Wrong default form | Explain KwikPen versus auto-injector versus vial, with the $299 versus $1,074.09 difference. The 45-day condition applies only to the 7.5 to 15 mg KwikPen purchase offer and runs from delivery or receipt. Re-quote the 5 mg SKU. |
| Insurance not found | Offer another plan, card photo, or self-pay at $100. Do not imply coverage. |
| PA required | Explain who submits, the expected several business days, the patient's financial responsibility, and the cash alternative. Track submission receipt and approval scope. |
| PA denied | Explain the denial reason, appeal rights and deadline, cash price, and alternative drug. Do not promise a reversal. |
| Pharmacy has no Rx | Confirm the NCPDP id, resend, or reroute. Give the patient a case owner and a next update time. |
| Out of stock | Offer a switched pharmacy or mail order, state the new price, and cancel the old order to avoid a duplicate fill. |
| Side effects | Triage severity. Emergency symptoms receive immediate emergency-services direction. Suspected pancreatitis requires stopping tirzepatide and immediate clinician contact or urgent assessment, not a paid visit or next-shift wait. Persistent vomiting, diarrhea, dehydration, severe abdominal pain or gallbladder symptoms need same-day clinical assessment and renal-function review. Do not let a $30 to $100 visit fee delay urgent triage. |
| Hypoglycemia and diabetes drugs | For insulin or a secretagogue, document whether dose reduction is indicated, the glucose-monitoring plan, hypoglycemia signs and the escalation route. Do not adjust another prescriber's insulin without coordination. |
| Cold chain and storage | Refrigerate at 2 to 8 C, never freeze; room temperature means no more than 30 C. Total room-temperature exposure is cumulative. Never use a previously frozen product. Single-dose pen or vial: up to 21 total days at 30 C or below, then discard. Unopened multi-dose vial or KwikPen at room temperature: discard after 30 days. Opened: discard after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first. Assess any damaged or warm product with the pharmacist; do not tell the patient to re-chill and inject. |
| Savings and coordination of benefits | Verify the current program, product and presentation, approved-use eligibility, government-program exclusion, pharmacy, quantity and days supply, caps and expiration. Record the primary claim outcome, any permitted secondary claim, approval or rejection, remaining cap and the patient's accepted price. Explain a denied savings claim before accepting a replacement cash price. |
| Missed dose | Take within 96 hours, otherwise skip and resume the regular day. The weekly day may change if at least 72 hours separate doses. Prolonged interruption needs clinician review before restart. Do not double dose. |
| Contraception | Tirzepatide delays gastric emptying and can reduce oral contraceptive exposure. Counsel on a non-oral method or backup for 4 weeks after initiation and after each escalation; repeat at week 4. Record the advice. |
| Supplies | Confirm the device, needle type, sharps disposal, and whether the box includes what the patient needs. No needle SKU was observed in the catalog; the pharmacy may supply or co-dispense. |
| Refund | Visit fee if canceled at least 24 hours ahead. A lab refund may be requested within 6 months of purchase if the sample has not been collected; eligible refunds have no fee deduction. No refund for service provided. |
| Records | Verify identity, log the request, route to the custodian for the relevant entity, and track the applicable deadline. Account closure is not medical-record deletion. |
| Stop or transfer | Stop the prescription, cancel future orders, explain billing, and provide records. |
| Privacy request | Verify identity, log the request, and route to the privacy officer. |
11.4 Compliance artifacts
| Artifact | Status | Evidence |
|---|---|---|
| LegitScript certification | Badge and outbound link in the footer | [F:F8] |
| HIPAA Notice of Privacy Practices | Live, last updated 2025-11-03, issued by the PCs | [F:F8] |
| Privacy notice | Live, last updated 2026-09-02, Path Healthcare Systems Corp. | [F:F8] |
| Telehealth consent | Emerald consent plus a separate Vital consent naming delegated entities | [F:F8] |
| Vendor BAAs | Not observed; no subprocessor list | [F:F8] |
| Pharmacy licensure | No verification UI or field recovered | [F:F8] |
| NP collaborative practice agreements | Managed by a dedicated licensure manager | [F:F8] |
| Prescriber licensure | State per booking, 50 states plus DC claimed, server-side filter; enforcement unverified and invalid state XX was accepted at availability |
[F:F8] [B:§5] |
| CPOM and Friendly PC | Five PCs by state; NPPES addresses and jurisdictions differ; state-of-care to entity to clinician mapping unverified, not proof of a defect | [F:F8] [D:D0.3] |
| PCI | Stripe and Trust Commerce | [F:F8] |
| Identity | Persona wired for some flows; GLP-1 trigger unknown; manual attestation fallback | [F:F8] [B:H22] |
| Good-faith estimate | No compliant estimate artifact recovered; per-SKU prices only. Required timing: 1 business day for 3 to 9 business days ahead, 3 business days for 10 or more ahead or a pre-scheduling request | [PUBLIC https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate] |
| Records custody and retention | No complete schedule, export endpoint or audio-retention policy recovered. HIPAA documentation floor is 6 years; state chart retention varies; define S3 lifecycle for cards and lab PDFs and a post-sign-off audio policy | [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.530] [PUBLIC https://www.law.cornell.edu/cfr/text/45/164.524] |
11.5 KPIs per stage
| Stage | KPI | Definition | Current value | Evidence |
|---|---|---|---|---|
| A | Organic landing conversion | Sessions that start signup | Not observable | [A:A2] |
| A | Wrong-price exposure | Sessions that view the $1,074.09 default | Not observable | [A:A5.1] |
| B | Signup completion | OTP verified to patient record | Not observable | [B:B7] |
| B | Verified match rate | Autofill success over attempts | Not observable | [B:§5] |
| B | Insurance success rate | Eligibility confirmed over attempts | Not observable | [B:B9] |
| B | Questionnaire completion | Submitted over started | Not observable | [B:B11] |
| B | Off-ramp rate | Off-ramps over completions, by type | Event exists, value not observable | [B:B11] |
| C | Booking conversion | Paid bookings over completed screens | Not observable | [C:C7] |
| C | No-show and cancellation | No-show events over booked eligible encounters, independent of fee assessment | Not observable | [C:C9] [CODE utils/cancellationFeeUtils.ts:43-53] |
| C | Lab attach rate | Lab orders over visits | Not observable | [C:C15] |
| C | Lab collection rate | Collected over ordered | Not observable | [C:C20] |
| D | Visit completion | Completed over booked | Not observable | [F:F3.2] |
| D | Prescription rate | Rx finalized over completed visits | Not observable | [D:D8] |
| D | Time to prescription | Visit start to Rx finalized | Not observable | [D:D8] |
| E | Time to fill | Two measures: Rx finalized to dispense, and checkout to dispense. Include PA delay and abandoned orders | Not observable | [D:D11-D17] |
| E | Direct-pay share | LillyDirect or Amazon over all fills | Not observable | [D:D12] |
| E | Dispense confirmation | Confirmed dispense over transmitted Rx | No dispense event recovered | [E:E1.3] |
| E | Possession confirmation | Patient-confirmed possession over dispensed | No possession event recovered | [INFERENCE: common practice] |
| E | PA submission to decision | Business days from submission to payer decision; approval is not a paid claim | No PA case event recovered | [D:D5.2] [INFERENCE: common practice] |
| F | T0 completeness | Patients with a recorded or patient-reported first dose over patients with a dispense | No T0 event recovered | [INFERENCE: common practice] |
| F | Check-in completion | Check-ins completed by T+20 over patients due | Not observable | [E:E6] |
| F | On-time transition | Second fill in hand by T+28 over patients with a recorded T0 | Not observable | [E:E5] |
| F | Escalation rate | Side-effect or adjustment visits over active patients | Not observable | [E:E16] |
| F | Second-fill persistence | Patients with a second fill over patients with a first fill; a dispensing measure, not adherence | Not observable | [E:E8] |
| F | Clinically approved continuation | Patients continued by a clinician over eligible patients | Not observable | [E:E7] |
| F | Intentional stop with transition | Documented stops with a transition plan over documented stops | Not observable | [E:E11] |
| F | Support contacts per patient | Conversations or SMS over active patients | Not observable | [E:E3] |
Proposed target bands, for design discussion only and not observed GM service levels: OTP verification above 90 percent; eRx acknowledgment within 15 minutes for at least 98 percent; PA submission within 1 business day; check-in started by T+18 for at least 85 percent; second box in hand by T+27 for at least 90 percent; critical lab call immediate. [INFERENCE: proposed targets]
12. Discrepancies and open questions
12.1 Conflicts between sources, resolved or open
| # | Conflict | Stronger evidence | Resolution | Status | Evidence |
|---|---|---|---|---|---|
| 1 | Zepbound "from $299" versus a default SKU at $1,074.09 | Live cash price per SKU | Two SKUs: 710641 KwikPen $299, 710642 auto-injector $1,074.09; the family default is the expensive one |
Resolved, product defect remains | [A:A5.1] [LIVE /api/external/medication_option_skus/710642/cash_price] |
| 2 | Lab components sum to $141.58 but total is $86.58 | Live lab_skus plus component code |
total_cash_price is test price plus $15 clinical fee; platform, order and collection fees are outside the total. Panel 503263 returns $40 platform, $6 order, $9 Quest collection |
Resolved | [C:C4.3] [F:F5.2] [LIVE /api/external/lab_skus/503263] |
| 3 | Clinical fee $15 versus $30 | Live data on 10 SKUs | $15.00 is live; $30 is only the client fallback when the field is missing | Resolved | [C:C4.3] [CODE types/enums/lab-pricing-constants.ts:8] |
| 4 | Chat price $30 versus $35 | Live sku_options |
$30 live; $35 is a code fallback | Resolved | [D:D5.4] [LIVE /api/external/sku_options/300543] |
| 5 | Cancellation fee amount | Policy page plus client fallback | Policy does not publish an amount; $25 is the client fallback; video only; Medicaid exempt | Open | [C:C4.4] [CODE utils/cancellationFeeUtils.ts:24-26] |
| 6 | Number and states of Friendly PCs | Legal docs, NPPES, privacy notice | Names and recorded addresses differ across sources. The state-of-care to furnishing entity to clinician to billing NPI mapping is unverified; address differences alone do not establish a licensure or CPOM defect | Open | [LIVE /terms-of-service] [LIVE /privacy-policy] [PUBLIC NPPES] [F:F7] |
| 7 | 37 versus 38 states in Care::Plan | Client map | The 37-state map is a shared UI grouping across care actions, not a Care::Plan enum; the 38th state and the server enum are unverified | Resolved as a UI count, open as an enum | [F:F7] [CODE components/CareActions/careActionSection.ts:40-92] |
| 8 | "We take care of prior authorizations" versus no PA contract | Assignment of benefits plus API inventory | Marketing claim; AOB places responsibility on patient or referring physician; no dedicated PA case or submission contract was recovered. Staff may work in payer portals | Open, ownership unclear | [D:D5.2] [LIVE /assignment-of-benefits] |
| 9 | LillyDirect is one partner or many | LillyDirect FAQ plus NPPES | NCPDP endpoint is LillyDirect Pharmacy LLC; dispensing is by Amazon, Fuze Health, Gifthealth, Prescryptive, or Walmart. Gifthealth publishes a different self-pay NCPDP 3692539; product-level routing is unverified |
Resolved as a set, open as routing | [D:D0.3] [LIVE https://www.lilly.com/lillydirect/faq] [PUBLIC https://www.gifthealth.com/faq-topics/prescriptions-getting-started] |
| 10 | in_stock in the data model versus live payload |
Live pharmacy_comparisons |
No inventory field live | Resolved, model is stale | [D:D0.3] [LIVE pharmacy_comparisons] |
| 11 | gm_card and pharmacy_delegated versus cash and pharmacy_delegation |
Client helper literals plus reconstructed OpenAPI | Source and specification differ. The OpenAPI is explicitly reverse-engineered, so this is not a demonstrated server enum defect; the authoritative BillingType is unverified |
Open, blocks reconciliation | [D:D5.4] [DOC openapi.yaml:1-8,257-262,1241-1246] |
| 12 | Pharmacy order state chain versus client contract | Client API plus data model | Four-state sequence is a dossier hypothesis; client exposes a state string plus cancel and switch flags. No ack, dispense or tracking field recovered; server feed unknown | Open | [E:E7] [CODE lib/store/api/pharmacyOrderApi.ts:15-24] |
| 13 | Lilly page CTA to 201448 with allows_first_fill:false |
Live SKU data plus page | New starts should use 300543; the CTA is a funnel mismatch |
Open, intent unknown | [D:D0.3] [LIVE /p/lilly/weight-loss] |
| 14 | Prescription quantity units | Live PDP payloads | Zepbound KwikPen 2.4 "Injection pens", auto-injector 2.0, Mounjaro 1.0; units look like mL mislabeled | Open, do not generate quantity from it | [D:D0.3] [LIVE product_detail_pages] |
| 15 | ZeroTouch as a modality | Live pages and Catalog | Only a display label in the briefing; no live occurrence | Resolved | [A:A5.2] [F:F0.1] |
| 16 | 3,184 sitemap /s/ URLs with noindex brand pages versus indexable orphans |
Live robots and sitemaps | Brand /s/ pages are noindex, /dp/ is indexable but absent from sitemap and internal links |
Open, ownership unknown | [A:A2.1] |
| 17 | redirect_url points to a Vercel host behind SSO |
Live Set-Cookie plus host behavior | If consumed as an absolute URL, the patient hits Vercel SSO | Open | [A:A8] [LIVE Set-Cookie headers] |
| 18 | "$30 typical insurance copay" for labs versus insurance_price: null |
Live lab SKUs | The $30 is an estimate constant, not a benefit | Resolved | [F:F5.2] [CODE types/enums/lab-pricing-constants.ts:13] |
| 19 | "80% of customers pay $25 or less" | Marketing copy only | Not independently verified | Open, marketing claim | [LIVE /p/lilly/weight-loss] |
| 20 | Support hours and contact sprawl | FAQ, consent, widgets, evidence-E and evidence-F | Same 12-hour support window, different labels; individual clinician shifts are 4 to 6 hours inside it. Contacts include help@generalmedicine.co, hello@generalmedicine.co, support@navhealth.co, (801) 251-6055 and (801) 255-6051. Tenant, purpose and ownership need reconciliation before publishing one DTC contact | Open | [F:F3.2] [LIVE /faq] [LIVE /telehealth-informed-consent] [E:E3] |
| 21 | Zendesk as patient support or clinician chat | Physician posting plus patient bundle | Confirmed clinician chat; patient support boundary unknown | Open | [F:F3.2] [LIVE Ashby FT Physician] |
| 22 | Metabase is publicly reachable | Live GET | Login shell reached; the reviewed response requires sign-in. Unauthenticated access to protected data was not established; SSO and permissions need review | Open, security review | [F:F4.1] |
| 23 | 5-phase GLP-1 progression | Public guide plus SKU prices | Synthesis, not an observed pathway object | Open | [F:F0.1] [DOC briefing slide 35] |
| 24 | Video available in all 50 states versus licensure coverage | Live sku_options plus posting requirements |
Video option returned for all states; clinician supply, licensure and state enforcement not guaranteed | Open | [B:B12] [F:F3.4] |
| 25 | signup_complete may not fire on the GLP-1 CTA path |
Code mount point plus redirect | Tracker mount, fetchUser, analytics availability and a local flag all gate the call. Firing on this path was not observed |
Open | [A:A8] [CODE components/SignupTracker.tsx:16-98] |
| 26 | price_guarantee_eligible:false versus checkout price_guaranteed flags |
Live SKU plus analytics | No guarantee on this path; checkout flags may be generic | Resolved, no guarantee | [A:A5.4] [CODE lib/analytics/checkoutAnalytics.ts:63-64] |
| 27 | Lab results "48 hours" | Product copy only | No measured SLA | Open | [C:C21] [LIVE /resources/labs-faqs] |
| 28 | Insurance discovery vendor | Verified candidate plus Waystar hosts | Both plausible; no payload observed. Diagram uses "Eligibility service" and "Clearinghouse" | Open | [B:H5] [B:H8] |
| 29 | Persona trigger for GLP-1 | Code routes plus generic pre-visit requirement | Trigger unknown; a later gate cannot be excluded | Open | [B:H22] [CODE lib/store/api/updatesApi.ts:76-80] |
| 30 | Who collects the $299 | Public article plus order schema | Pay-ahead is retail-only; mail order pays the pharmacy; schema does not distinguish | Open | [D:D4.3] [C:C13] |
| 31 | Mounjaro is described as a Zepbound variant | Mounjaro PI plus evidence-D catalog | Separate T2D and CV-risk indication, separate NDC, retail-only observed route at $552.28 to $565.63; Zepbound self-pay ladder does not apply | Resolved as a separate branch, price snapshot open | [PUBLIC Mounjaro PI §1] [D:D4.2] |
| 32 | Cash mail order shown as two payments | Pay-ahead article plus evidence-D | Mail order is excluded from GM pay-ahead; patient pays the dispensing pharmacy once. Diagram corrected | Resolved | [D:D4.3] [LIVE /resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup] |
| 33 | Week-4 check-in shown at T+28 | Four-dose supply arithmetic plus generic criteria API | One KwikPen supplies four weekly doses, used by T+21; the next dose is due T+28. Starting refill work at T+28 can miss it. Proposed control is T+14 to T+18 refill start and backward planning; T+21 eRx alone does not guarantee mail-order delivery | Open, proposed control | [PUBLIC Zepbound PI §2.1] [PUBLIC https://www.lilly.com/lillydirect/faq] [E:E5] |
| 34 | Click clock and treatment clock share one column | Timeline arithmetic | E0 is click; T0 is first actual dose, patient-reported or evidenced. The clocks differ by the unknown Dstart; no bounded interval is established | Resolved in text, data gap remains | [INFERENCE] |
12.2 Open questions
- Which Google queries drive organic sessions and conversions? No Search Console export was available.
- Is GM running paid media at scale, and are conversions uploaded server-side? No pixel exists.
- Does the post-auth flow use the full
redirect_urlor only its pathname? - Does
signup_completefire on the Lilly and GLP-1 CTA path? - Who owns sitemap generation, and why are noindex URLs included while indexable pages are omitted?
- Is the $1,074.09 default a clinical preference or a catalog artifact?
- Which Zepbound SKU do paid campaigns and prescribers actually use?
- Are the vial SKUs real products, and why is there no cash price?
- Is there a BAA with Segment, Datadog, Google, OneSignal, Sanity, Slack, Metabase, or the LLM vendor?
- Is 100 percent session replay lawful on clinical pages?
- Is ZeroTouch a product or only a Catalog label?
- What is the cancellation fee amount?
- What pharmacy margin, if any, does GM earn?
- Does the screening questionnaire branch on BMI or contraindications before booking?
- Are Obesity
300513and Weight Loss300312distinct protocols? - What is the exact state-to-PC and state-to-clinician matrix?
- Is the Vital and OpenLoop consent used for GLP-1, or legacy?
- Does any GLP-1 case use async clinical review?
- Who submits a PA, in what tool, and what is the p50 and p90?
- Does an approval cover a dose change, or is a new PA required?
- Can a patient attach a manufacturer savings card in GM checkout?
- Does the week-4 step require a paid visit, a questionnaire, or either?
- What are the clinical SLAs for chat, video start, and review?
- Is there a server-side dispense or rejection feed from any pharmacy?
- Does GM ingest carrier tracking?
- Is
default_quantitymL or pens? - Who collects and remits the $299 on mail order?
- Who sponsors the GM card BIN, and what is the discount formula?
- Is the client
pharmacy_delegateda typo, a legacy alias, or a real server value? - What is the lab bundle composition at week 4 for tirzepatide?
- What is the patient-facing critical-result SLA?
- Are at-home lab kits supported?
- Which LLM and prompt version draft the care plan and the patient copilot answers?
- What are the CarePathway phase values for GLP-1?
- Is Zendesk also used for patient support, and is a BPO behind 98528?
- What happens when weekend and evening clinical coverage expands?
- Who executes refunds, in what tool, and against what SLA?
- What is the medication refund policy for an uncollected or canceled fill?
- Are receipts emailed, and is there a tax line?
- How does the 104-employee count split across clinical, operations, support, RCM, and engineering?
- Does GM issue a good-faith estimate for self-pay patients, and in what channel?
- Is there an accessibility, interpreter, or caregiver path for intake and visits?
- Are pen needles and sharps supplies included, sold, or only counseled?
- Does GM confirm patient possession after delivery, or only rely on the carrier scan?
- Where is contraception counseling recorded at initiation and at each escalation?
- Is a first-dose administration date captured, and from what source?
- Is the HIE notice stored as a consent record, or only presented by continuing?
- What is the current Mounjaro cash quote, PA route and savings eligibility for the T2D branch?
- Does the backend enforce state licensure and professional-entity routing, or only filter the visible clinician pool?
- How many outside parties are mandatory on one real journey, as opposed to exchange entries in the register?
- Which PA submission channel and vendor are actually used, if any?
- Does any pharmacy send a dispense, rejection or tracking feed back to GM?
13. Evidence key
13.1 Tags
| Tag | Meaning |
|---|---|
[CODE path:line] |
Observed in the recovered first-party source under src/sources/first-party/ |
[LIVE url, date] |
Observed on the live public site or public API, read-only, on 2026-10-19 |
[DATA file → key] |
From a local dataset under osint/, for example internal_portals_recon.json or extracted_care_plans_and_journeys.json |
[DOC file §section] |
From a dossier, AlphaSense report, or briefing appendix |
[PUBLIC url] |
A public third-party source: label, vendor documentation, NPPES, manufacturer terms |
[E:§6 q14] |
Open question 14 in evidence-E.md section 6 |
[INFERENCE] |
Reasoning that is not directly observed; the basis is stated inline |
A:A1, B:B7, C:C4, D:D5.2 |
Step row or numbered subsection in the named evidence file. The step ID is the stable anchor; that row carries the exact code path, live URL, or dataset key. |
[B:§5] |
Section 5 of evidence-B.md, covering signup failure branches at evidence-B.md:128-136. [B:B5] is reserved for the Verified review-info step at evidence-B.md:29. |
H01 to H72 |
Register row in section 4 |
* on a register row |
On the cash path, including alternative pharmacy and lab channels |
Observed |
A specific source artifact or public response was inspected; not the full patient workflow |
Published |
A company or vendor representation, not a measured SLA |
Proposed |
A recommended future contract or control |
Recovery gap |
Implementation was not available in the inspected material |
Mapping gap |
This document omits a required step |
Inferred |
Deduced from hostnames, absence, or adjacent evidence; not seen directly |
13.2 Main sources
- Evidence files behind every
A:–F:tag (each step row and handoff row carries its exact code path, live URL, or dataset key): Evidence A: acquisition, Evidence B: account and intake, Evidence C: checkout and labs, Evidence D: clinical review and pharmacy, Evidence E: weeks 1 to 4, Evidence F: backoffice and operating model. Markdown originals sit beside each page. - Recovered consumer app (
src/sources/first-party/:app/,components/,lib/,contexts/,hooks/,config/,tenants/): browse in the Research Wiki source index. - Internal portal inventory:
osint/internal_portals_recon.json, covering Visitron 98 routes and 91 RTK operations, Catalog 47 routes and 106 operations, Referrals 18 routes and 27 operations, Provider Chat 20 routes and 14 operations. - Live SKU, questionnaire, and care-plan payloads:
osint/extracted_care_plans_and_journeys.json. - Sitemap and price census:
osint/live_sitemap_skus.json. - Infrastructure and NPI catalog:
osint/infra_npi_catalog.json. - Dossiers: architecture, API reference, data models, OpenAPI contract, market and leadership dossier, company overview.
- AlphaSense reports: company primer, Oct 19, expert calls, Oct 18, primer snapshot, Oct 18.
- Public manufacturer terms and labels:
https://zepbound.lilly.com/savings,https://www.lilly.com/lillydirect/faq,https://www.lilly.com/lillydirect/zepbound,https://pi.lilly.com/us/zepbound-uspi.pdf,https://pi.lilly.com/us/mounjaro-uspi.pdf. - Public vendor documentation:
https://docs.verified.inc/1-click-signup/overview,https://docs.verified.inc/1-click-health/overview,https://www.gifthealth.com/faq-topics/prescriptions-getting-started,https://docs.junction.com/lab/overview/orders-and-results,https://docs.junction.com/lab/results/critical-results,https://docs.junction.com/lab/workflow/redraws,https://surescripts.com/news-center/intelligence-in-action/interoperability/the-journey-of-an-electronic-prescription. - Public registries:
https://npiregistry.cms.hhs.gov/api/, NPI records1912889320,1285084467,1710671854,1447011267,1750195483,1174333975,1346050150. - Public policy pages:
/cancellation-policy,/refund-policy-labs,/assignment-of-benefits,/telehealth-informed-consent,/vital-informed-consent,/privacy-policy,/hipaa-privacy-practices,/faq,/resources/using-a-glp-1-for-weight-loss,/resources/labs-faqs,/resources/medication-faqs,/using-zoom,/clinician-hiring. - Legal and program references:
https://www.medicare.gov/coverage/weight-loss-drugs,https://www.cms.gov/initiatives/your-patient-rights/medical-bill-rights/get-help/guides-resources/what-good-faith-estimate,https://www.mbc.ca.gov/Resources/Medical-Resources/telehealth.aspx,https://www.law.cornell.edu/cfr/text/45/164.502,https://www.law.cornell.edu/cfr/text/45/164.524. - Hiring and operating model:
https://api.ashbyhq.com/posting-api/job-board/general-medicineand the full-time physician, 1099 physician, 1099 nurse practitioner, care coordinator, NP licensure, and RCM postings. - Public market context: Walmart and LillyDirect retail pickup release, CNBC vial price report, Pharmacy Times manufacturer-direct analysis.
13.3 Handoff count method
Raw handoff rows by file: A 23, B 22, C 15, D 18, E 18, F 25, total 121. The register has 72 rows after three operations: merging duplicate vendors that appear in several slices (Stripe, Twilio, Segment, Datadog, LaunchDarkly, Metriport, Particle, Athena, DoseSpot, Arrive, labs, pharmacies); splitting counterparties that were grouped in one raw row but have distinct mechanisms (LillyDirect endpoint versus dispensing pharmacies; Amazon versus other retail; Emerald versus Ruby and Centennial); and adding three handoffs required by the assignment but absent from the six tables (CMS NPPES, CMS Medicare GLP-1 Bridge, and the unidentified LLM provider). The staff identity plane is separated from the patient Cognito row.
13.4 Known limits
- No authenticated screen was observed. All account, checkout, pharmacy-order, and care-plan pages return 307 to
/loginwithout an account. - No pharmacy, payer, lab, BI, or records production system was accessed. A missing field in an inspected interface is a recovery gap, not proof of enterprise-wide absence.
- The click-to-first-dose interval is not measured. T0 is patient-reported or evidenced, never inferred from payment, eRx, dispense or delivery.
- The GLP-1 questionnaire text, the week-4 criteria set and blocking rule, the CarePathway phases, and the PA workflow are server-side and were not recovered.
- Internal portal behavior comes from the recorded operation inventory, not a live authenticated session.
- The mandatory-party count for one journey is not established. The register counts exchanges, companies, products and conditional branches separately.
- Prices and published program terms move. Every price above is a 2026-10-19 observation and should be re-probed before use in a contract or a forecast.